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Perivascular cells found in multiple organs give rise to mesenchymal 
stromal/stem cells or MSCs in vitro. These include adventitial cells (CD34+ 
CD146- CD31- CD45-) isolated from large vessels and pericytes (CD34- 
CD146+ CD31-CD45-) found in small vessels and capillaries. Both populations 
play a key role in tissue remodelling during injury and disease and display 
phenotypic and functional heterogeneity. However, specific stem cell 
properties of both populations are unknown. During my PhD, I have identified 
aldehyde dehydrogenase (ALDH) activity as a marker of stem cell-like 
perivascular cells. We performed RNA sequencing on perivascular cells 
isolated based upon high- or low ALDH activity. I found transcriptional 
differences that suggest different functions in vivo including progenitor capacity 
and interaction with the immune system. Interestingly, I found that ALDH1A1, 
which has been associated with stem cell properties, is the main isoform 
present in ALDH high adventitial cells suggesting their involvement in the 
regeneration process post-tissue injury. Whether these cells change in culture 
remains unclear. I found that ALDH subsets isolated from adventitial cells 
become similar both transcriptionally and functionally upon expansion in MSC 
culture. Conversely, pericytes seem to maintain a different identity compared 
to adventitial cells in vitro. I next analysed ALDH1A1 expression in pathological 
tissues. In human glioblastoma, I found that ALDH1A1 expression in 
perivascular cells changes suggesting their involvement in angiogenesis and 




showed changes in ALDH1A1 expression distribution, suggesting their 
contribution to the regeneration process. 
 In conclusion, my results show that ALDH high adventitial cells in large vessels 
mark a population of MSC progenitors expressing genes involved in processes 
such as angiogenesis and, matrix remodelling, amongst others. Importantly, I 
documented how culture conditions change these perivascular cells once they 
become MSCs in vitro. Finally, I showed that ALDH1A1 expression and cell 


















Stem cells named “mesenchymal stem cells” that reside along blood vessels 
can be cultured and expanded in plastic dishes for clinical use for numerous 
diseases. In the tissues, some of these cells surround the large vessels and 
are called adventitial cells and some are found around small blood vessels, in 
which case they are called pericytes. They were shown to be directly involved 
in the healing process by either contributing to scarring or replenishing 
damaged tissue. However, the mode of action of these stem cells is not well 
understood, despite their high therapeutic value. They are  heterogeneous and 
thus, it is crucial to investigate whether perivascular stem cell subsets play 
distinct functions. This will help us to better understand the treatment and to 
design better strategies to treat patients according to the particular disease in 
which these subsets are involved. In my thesis, I describe a novel population 
of adventitial cells with high activity of the enzyme family named ALDH. These 
enzymes are involved in cell detoxification, but are also indicative of stem cell 
properties. I successfully isolated adventitial cells with high ALDH activity from 
human fat and characterised them in vitro. Furthermore, I found that ALDH1A1 
is almost exclusively expressed in adventitial cells in different tissues. This was 
translated into mouse tissues, where we saw ALDH1A1 being expressed after 
injury in skeletal muscle in immature muscle fibres suggesting a role in 
proliferation. Overall, this research provides evidence of the existence of a 
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1.1 Mesenchymal stem cells  
1.1.1 Definition and discovery of mesenchymal stem cells 
The presence of cells with osteogenic potential in the bone marrow was first 
described by Tavassoli using entire fragments of bone-free bone marrow 
(Tavassoli and Crosby, 1968). However, these cells were first described in 
detail by the soviet scientist Alexander Friedenstein when he found that a 
population of adherent cells from the human bone marrow gives rise to clones, 
could give rise to fibroblasts in culture. He observed that these cells do not 
belong to the hematopoietic cell lineage and could give rise to bone and 
cartilage-forming cells.  (Friedenstein et al., 1966; Friedenstein et al., 1974).  
 
Owen and Friedenstein (Owen and Friedenstein, 1988) and Piersma  (Piersma 
et al., 1985) further characterized these cells and  along with other 
investigations (Friedenstein et al., 1987; Wakitani et al., 2002) and established 
that these cells, isolated by plastic adherence, can form osteoblasts, 
chondrocytes, adipocytes and myoblasts. Hence, multipotent progenitors 
cultured from total mouse bone marrow were shown to exhibit developmental 
plasticity, giving rise to diverse mesodermal cell lineages. The term 
“mesenchymal stem cells” or MSCs was first used by Arnold Caplan (Caplan, 
1991). He proposed a parallel with the stem cells at the origin of mesodermal 
tissues in the embryo, and was also the first one to grow these cells from 
human tissues (Caplan, 1991). They were described as non-hematopoietic 




lineages such as adipocytes, chondrocytes and osteoblasts (Chamberlain et 
al., 2007) (Figure 1). 
 
Haynesworth and colleagues  (Haynesworth et al., 1992b) cultured and 
expanded bone marrow MSCs from the iliac crest of human donors showing 
for the first time that human bone marrow also contains cells with osteogenic 
potential. The same group created antibodies identifying SH-2 and SH-3 as 
unique cell surface antigens on MSCs (Haynesworth et al., 1992a). Later Barry 
and colleagues described the ligands of the SH-2 and SH-3 antibodies as 
CD105 and CD73, respectively (Barry et al., 1999, 2001). MSCs could be now 
selected on ability to adhere and proliferate in culture, expression of cell 
surface markers: CD73, CD90, CD105, CD44, CD124 (Haynesworth et al., 
1992a; Barry et al., 1999, 2001) and potential to give rise to mesodermal cell 
lineages in vitro. Then Pittenger isolated presumptive MSCs from over 50 
donors that were expanded, all responding positively to osteogenic, 
adipogenic and chondrogenic inductions. Cells displayed normal karyotype 
and telomerase activity (Pittenger et al., 1999). 
 
Bone marrow was the first organ to be studied as a source of MSCs. Later, 
cells isolated from adult adipose tissue, which remains a major provider of 
MSCs, demonstrated similar multipotency ex vivo (Zuk et al., 2002; Rodriguez 
et al., 2005; Xu et al., 2005; Rodeheffer et al., 2008). These findings were 




all vascularized tissues (Gronthos et al., 2000; Arai et al., 2002; Romanov et 
al.,  2003; Mansilla et al., 2006; Zheng et al., 2007; Crisan et al., 2008) 
 
Human MSCs were first isolated from the bone marrow as mentioned before 
(Caplan, 1991) and since then, they have been isolated from the stroma of 
practically all post-natal tissues (Zuk et al., 2002; Meirelles et al., 2006; Sagar 
et al., 2018). However, MSCs are a mixed population of cells. The International 
Society for Cellular Therapy (ISCT) set the following minimal criteria to identify 
an MSC (Dominici et al., 2006): 
 
• Be adherent to plastic 
• Express the cell surface markers CD105, CD90, CD44 and CD73 
• Lack  expression of the surface markers CD45, CD19, CD14, CD11b, 
CD34, CD79α, and HLA-DR 
• Be able to differentiate into osteocytes, chondrocytes and adipocytes. 
 
In addition to their differentiation properties in vitro, mesenchymal stem cells 
can also provide in vitro support to hematopoietic stem cells (Majumdar et al., 
1998), and are considered of high interest for cell therapy due to their 
regenerative and immunomodulatory properties. Indeed, so far, MSCs have 















Figure 1 Mesenchymal stem cell tri-differentiation potential. 
MSCs can differentiate into cell types of the mesodermal lineage such as adipocytes, 




1.1.2 Immunomodulatory properties of MSCs 
Mesenchymal stem/stromal cells have regenerative and immunomodulatory 
properties that make them highly valuable for cell therapy (Kode et al., 2009). 
The first medical use of MSCs was in 1995 using bone marrow cells from 
patients with hematologic malignancies in complete remission, which were 
subsequently expanded and reinfused to patients (autologous 
transplantation). MSCs have also been used to treat patients with breast 
cancer (Koç et al., 2000) and since then these experiments have been used in 
clinical trials. It is now well documented that MSC benefits are due mainly to 
the release of growth factors and cytokines along with extracellular vesicles to 
activate cell proliferation, prevent apoptosis, and ultimately improve 
regenerative responses (Shigemoto-Kuroda et al., 2017; Yang et al., 2017). 
Furthermore, MSCs can also modulate responses by interacting with different 
immune cells either by direct contact or the release of soluble factors (Figure 
2). However, the mechanisms by which MSCs prevent inflammation and 
promote healing are not fully understood.  
 
The interaction of MSCs with immune cells including T cells and  natural killer 
cells require direct contact through different mechanisms. For example, 
engagement of  PD-1 (programmed death 1) and its ligands PD-L1 and PD-L2 
is required for inhibition of proliferation and subsequent signalling  by cytokines 
(Augello et al., 2005). Likewise, the release of antibodies by B cells is also 




cells are not well understood, and probably require other intermediates (Fan 
et al., 2016). Indeed, CD3+ T cells are needed for B-cell inhibition (Rosado et 
al., 2014).  
There are multiple reasons why MSCs do not activate the immune system. 
These include the lack of expression of co-stimulatory molecules CD80 and 
CD86, required for immune activation, the absence of major histocompatibility 
complex (MHC) class II antigens and low expression of MHC class I (Krampera 
et al., 2003; Le Blanc et al., 2003; Nauta and Fibbe, 2007). On the other hand, 
soluble factors are also required for immune modulation by MSCs. The main 
mediators of MSC-driven immune modulation are indoleamine-pyrrole 2,3- 
dioxygenase (IDO), prostaglandin E2 (PGE2) and cyclooxygenase 2 (COX-2) 
in the presence of pro-inflammatory cytokines (Ryan et al., 2007). For 
example, PEG2 is involved in the production of anti-inflammatory IL-10 by 
macrophages (Németh et al., 2008) and blocks differentiation of monocytes 


















Figure 2 Immunomodulatory properties of MSCs. 
 Regulation of the immune response by MSCs is a complex mechanism. MSCs can supress 
naïve and memory T cells and inhibit proliferation of B cells.  MSCs reduce IFN-γ production 
and prevents cytotoxicity of Natural Killer (NK) cells through soluble factors. Moreover, MSC 
can inhibit the differentiation of monocytes into mature dendritic cells (DC). Adapted from Kode 




1.1.3 Regeneration mechanisms of MSCs 
In addition to their immunomodulatory properties, MSCs also promote 
regeneration by direct differentiation (although variable) and by promoting the 
proliferation of host endogenous cells by the release of soluble factors. One of 
the best known mechanisms of MSC-driven regeneration is promotion of 
angiogenesis. Direct injection of perivascular MSC-progenitors into ischemic 
hearts resulted in improvement of vascularization in the cardiac muscle (Chen 
et al., 2015), and moreover, direct delivery of bone-marrow-derived MSCs 
improved heart regeneration after myocardial infarction (Amado et al., 2005). 
This improvement after MSC treatment is due to the release of different factors. 
For example, MSC secrete vascular endothelial growth factor (VEGF) which 
triggers angiogenesis (Sorrell et al., 2009), and nitric oxide synthase (NOS) 
that prevents fibrosis (Ferrini et al., 2002). 
 
Lastly, MSCs release exosomes/microvesicles that are non-cellular 
transporters of regulatory RNAs, proteins and lipids. These extracellular 
vesicles (EV) can induce proliferation of progenitors and prevent scar 
formation (Lai et al., 2010; Liu et al., 2018). For example, in a model of carbon 
tetrachloride (CCL4)-induced liver fibrosis, MSC-derived exosomes alleviated 
tissue damage (Jiang et al., 2018). 
 
Although the use of MSC-derived EVs for cell therapy seems promising, more 




For example, EVs are themselves highly heterogeneous, and evolving criteria 
for their isolation and characterization represent important guidelines for 
standardization in the field (Théry et al., 2018). 
 
 
1.1.4 MSCs in clinical trials and alternative approaches to 
improve clinical outcome 
MSCs have been used clinically for more than two decades, and over 980 
registered MSC trials are listed by the FDA (www.clinicaltrials.gov). Results 
have often fallen short of expectations though. In a phase III trial using MSCs 
(Prochymal) for treatment of steroid-refractory graft-versus-host disease 
(GVHD), MSC treatment showed no significant difference after 28 days 
compared to the placebo control (Martin et al., 2010). However, the 
stratification of the data showed thatchildren responded better to MSC 
treatment, leading to approval of Prochymal in Canada (Reicin et al., 2012). 
With similar results, cardiopoietic primed bone-marrow derived MSCs were 
used to treat ischemic heart failure by the Belgium based company Celyad with 
good preliminary results. However, further trials showed no significant 







Despite many setbacks in clinical trials, MSC therapy has been approved in 
different countries. In Japan, the use of MSCs was approved after the Act on 
the Safety of Regenerative Medicine and the Pharmaceuticals, Medical 
Devices and Other Therapeutic Products Act were introduced (Sipp, 2015). 
More recently, the European Medicines Agency (EMA) recommended the 
approval of Alofisel to treat Crohn’s disease (Sheridan, 2018). Overall, the use 
of MSCs for cell therapy is becoming a reality.  
 
One of the main problems regarding MSC therapy is the variable nature of the 
results. Factors like tissue of origin, donor gender and medical history can 
influence clinical outcomes. Moreover processing of the tissue, culture 
conditions, freezing and thawing of cells along with the administration routes 
are other factors to be taken into consideration (reviewed by Galipeau and 
Sensébé, 2018). Lastly, MSCs are expanded for long periods of time to obtain 
enough cells for therapeutics, which induces changes in gene expression and 
allows clonal selection, therefore affecting biological properties and the 
heterogeneity of the cell population.  
 
The heterogeneity of MSCs along with the diversity of the tissues they are 
isolated from adds to this complexity in the nature of MSCs. The most 
commonly used tissue to isolate MSCs are bone marrow, adipose tissue and 
cord blood (Gao et al., 2016), although MSCs can be obtained from all 




al., 2012) and brain (Lojewski et al., 2015). It has been documented that the 
tissue of origin can influence the secretome of MSCs  (Kalinina et al., 2015). 
Furthermore, MSCs derived from diseased donors have shown negative  
results (Dzhoyashvili et al., 2014). Finally, the age of the donor is a key factor 
affecting MSC efficacy. For example,  MSCs isolated from neonatal tissues 
show a longer lifespan, higher proliferation rate and differentiation potential 
when compared to adult tissues (Donders et al., 2017).   
 
The ideal conditions for MSCs to be used for cell therapy include the use of 
medium with no animal products.  One of the most common additives for cell 
culture is fetal calf serum which is not well characterized, and properties vary 
between batches. To obtain high number of cells MSCs need to be expanded 
in vitro. This cell expansion requires the passaging of cells  in which proteolytic 
enzymes are used, thus inducing cell damage (Penna et al., 2015). 
Furthermore, during culture conditions MSCs are cultured at high oxygen 
levels that may compromise the therapeutic benefits of MSCs. Native 
perivascular cells (MSC progenitors) tissue environments range between 1 
and 7% O2; during culture cells sense an oxygen concentration of 20%, which 
may cause oxidative stress affecting viability, and eventually leading to 
senescence. Indeed, hypoxia has been shown to increase proliferation of 
MSCs (Zhu et al., 2016). Moreover, cells under hypoxic conditions maintain 
their undifferentiated status and multipotency (Basciano et al., 2011). Hypoxia 
also improves angiogenesis (Bader et al., 2015) and migration toward the site 




Contrasting results using MSCs is likely due to the combination of variables 
such as donor demographics, cell processing technical conditions and organ 
source. Therefore,  cell therapy using MSCs need to be tailored to every 
specific type of injury or disease which may include the pre-conditioning of cell 
to enhance clinical outcome and screening of the host’s immune response  
(reviewed in Pittenger et al., 2019). 
 
Despite intense use of these cells for cell therapy, the fate of transplanted 
MSCs is not well documented (autologous, allogeneic, or xenogeneic 
transplantation). Injected MSC direct contribution to new tissue formation is 
minimal, with only a small proportion of xenogeneic (human) cells engrafting 
mouse tissues (Chen et al., 2015b), and those cells not engrafted cleared from 
the tissue 72 h post administration (Lee et al., 2009; Gholamrezanezhad et al., 
2011; von Bahr et al., 2012) .Nonetheless, this clearing of MSCs may be of 
clinical interest.  It has been shown that dying transplanted MSCs engulfed by 
recipient macrophages release immunosuppressive soluble factors (Galleu et 
al., 2017), suggesting that death within host tissues contributes directly to the 
beneficial effects of MSCs. 
 
Different approaches to improve the clinical benefit of MSC therapy have been 
used. For example, a suitable option to improve the benefit of MSCs is the use 
of scaffolds populated that, when engrafted, provide higher regeneration. 




Tissue engineering can be used to mimic organ microenvironment for organoid 
culture (Fatehullah et al., 2016) and may rely on 3-dimensional printing 
(Poldervaart et al., 2017). Tissue engineering can also be used to improve 
MSC residence after administration, to which aim MSC-based scaffolds have 
been used, using either biodegradable or non-degradable polymers to form 
hydrogel matrices (Park et al., 2018), which can be supplemented with growth 
factors. MSC based scaffolds systems have been used for bone and cartilage 
regeneration (Kim et al., 2019), as well as for the reproduction of blood vessels 
(Pinnock et al., 2016), cardiac tissue (Rashedi et al., 2017; Ichihara et al., 
2018), and skeletal muscle (Witt et al., 2017). Optimal tissue replacement 
efficiency relies on the physical characteristics of the scaffolds (Alakpa et al., 
2017; Jeon et al., 2017; Mouser et al., 2018), as each mechanical property can 
modify the fate of the transplanted cells. For instance, stiff matrices can be 
determinant to drive MSC differentiation into chondrogenic or osteogenic cell 
lineages (Alakpa et al., 2016), whereas softer substrates can favour myogenic 
development (Gilbert et al., 2010). In addition to stiffness, dimensionality and 
degradability of the matrix can regulate mechanisms critical for cell 
differentiation (Caliari et al., 2016).  
 
An alternative method to improve the delivery, engraftment and therefore 
clinical benefit of MSCs, is the use of  sorted perivascular presumptive MSCs 
for direct transplantation instead of cultured cells (Murray and Péault, 2015; 
James and Péault, 2019), the latter being susceptible to modifications 




Other aspect to consider is that the expansion of MSCs selects the fastest 
growing clones and after enough passages, the whole cell population becomes 
homogeneous (Selich et al., 2016). Furthermore, MSC clones have different 
mesodermal differentiation potentials (Muraglia et al., 2000). Following this 
rationale, the use of freshly sorted stromal cells with High ALDH activity in a 
model of hind limb ischemia has yielded striking results (Capoccia et al., 2009), 
documenting another dramatic difference between subpopulations of MSC 
ancestors that may be lost after culture.  
 
Another alternative for the use of uncultured cells relies on the administration 
of microfragmented adipose tissue, in which the microenvironment of 
perivascular progenitors is maintained (Vezzani et al., 2019).  This 
preservation of the niche sustains higher secretory activity, releasing abundant 
cytokines and growth factors (Vezzani et al., 2018).   In general, transplantation 
of uncultured cells may be ideal to improve clinical outcome, although numbers 
of cells obtained are lower than in culture conditions and may not be enough 








1.2 Blood Vessels as a Source of Mesenchymal 
Stem Cells 
Although mesenchymal stem/stromal cells have been used in numerous 
studies and clinical trials, the origin of these cells was not known. MSCs are 
typically isolated by adherence to plastic and selection by consecutive 
passaging. However, the true identity of MSCs remained unknown. The idea 
of a common precursor in the vasculature was proposed due to the presence 
of blood vessels in most organs (Crisan et al., 2008). One of the important 
observations to identify the MSC progenitor in vivo was the relationship 
between vascular density and MSC yield. Indeed, the higher the number of 
blood vessels in the tissue, the higher the yield of MSCs (da Silva Meirelles et 
al., 2008). The attention for the possible MSC progenitors was drawn to blood 
vessels. Indeed, pericytes  in capillaries and adventitial cells in larger vessels 
are MSC progenitors (Figure 3) (Crisan et al., 2008; Corselli et al., 2012).  
 
1.2.1 Pericytes as MSC progenitors  
Pericytes (PCs), also called mural or Rouget cells, are cells embedded in the 
basement membrane of microvessels. These cells were first described by 
Eberth and Charles-Marie Benjamin Rouget (Attwell et al., 2015). However, 
Zimmermann was the one who called these  “Rouget cells”  pericytes due to 
the proximity of these cells to endothelial cells (Zimmermann, 1923). Pericytes 
interact with endothelial cells  through different molecules and activate different 




others (Armulik et al., 2011).  One of the main functions of pericytes, similar to 
smooth muscle cells of large vessels, are vasoconstriction and vasodilation to 
regulate vascular diameter and the blood flow in capillaries (Rucker et al., 
2000). The expression of contractile proteins such as α-SMA, tropomyosin, 
and myosin in pericytes provides evidence of their function. These proteins are 
also produced in smooth muscle cells which is the source of confusion 
between the definition of a pericytes and a smooth muscle cell. Pericyte 
contractile function is regulated by many molecules. Pericytes respond to β-
adrenergic stimuli leading to relaxation, whereas α-adrenergic signals produce 
contraction (Rucker et al., 2000). Oxygen levels also regulate pericyte 
contraction. For example, hypoxia increases the contraction of pericytes in 
vitro and CO2 induces relaxation. 
 
 The function of pericytes in vivo has shown that they response to vasoactive 
substances in skeletal muscle (Hirschi and D’Amore, 1996). Lastly, pericytes 
have also been described to act as progenitor during injury (Dellavalle et al., 
2011). 
 
MSC progenitors were described to be in the perivascular niche. However, 
identifying pericytes is not easy since there are no specific markers for this cell 
type.  Crisan and colleagues identified pericytes as MSC progenitors 
expressing canonical MSC markers, and a set of surface markers including 




pericytes and MSCs. A combination of markers (CD146+ CD31- CD45- CD34-
), common between all organs has been used to isolate pericytes from all blood 
vessels (Crisan et al., 2008).  
 
Pericytes are MSC precursors, and their function as progenitors in vivo has 
been described. For example, tissue resident pericytes in skeletal muscle can 
differentiate into muscle fibres (Dellavalle et al., 2011) and pericytes in adipose 
tissue are adipocyte progenitors(Tang et al., 2008). In addition some pericytes 
expressing gli1 differentiate into myofibroblasts (Kramann et al.2015). 
However, the contribution of pericytes in the in vivo setting has been 
questioned. Indeed, Guimarães-Camboa showed that pericytes in different 
organs are at the origin of MSCs in culture but do not contribute to other 
lineages in aging and injury of different tissues in vivo (Guimarães-Camboa et 
al., 2017). However, Tbx18, the marker used to trace pericytes, is questionable 
since not all pericytes express it.  This suggests that not all pericytes contribute 
to regeneration. Moreover, this work was performed in mice and thus there is 
no clear evidence that this conclusion applies to human. Our own studies found 
that pericytes are less primitive compared to other perivascular cells and 
express genes more related to their function such as blood flow regulation than 
to “stemness” (Hardy et al., 2017). However, as  mentioned,  some pericytes 





1.2.2 Are adventitial cells the true MSC progenitors in vivo?  
Large blood vessels, arteries and veins, consist of three layers: tunica intima, 
tunica media and tunica adventitia (in veins there is less smooth muscle and 
connective tissue). The innermost layer, the tunica intima, is comprised of the 
endothelium, connective tissue (mainly collagen, fibronectin and other 
extracellular matrix molecules). The middle layer or tunica media is formed 
primarily by smooth muscle cells and is the thickest layer. This layer is 
especially important since it provides support and can change diameter and 
regulate blood flow and pressure. The tunica adventitia is the outermost layer 
and consists of connective tissue, fibroblasts, inflammatory cells, vasa 
vasorum and other cells (Moreno et al., 2006).  
 
For a long time, the adventitia layer was regarded as a support connective 
tissue containing collagen and fibroblasts only. However, in the last years 
many studies have identified this layer as a dynamic compartment for cell 
trafficking to and from the vessel, and showed that it also participates in growth 
and repair (Majesky et al., 2011). The adventitial layer plays key roles in 
biological processes such as the retrieval, integration, storage and release of 
cellular regulators of vessel wall function. It is the most complex layer of the 
large vessel and is comprised of a variety of cells including progenitor cells, 
fibroblasts, immunomodulatory cells, vasa vasorum endothelial cells and 




 Upon injury, cells in the adventitia layer have been proposed to differentiate 
into myofibroblasts, and to migrate to the inner layers of the vessel wall to 
regulate vascular remodelling (Siow et al. 2003; Stenmark et al. 2006). Cells 
in the adventitia have also been described as mediators of remodelling by 
regulating reactive oxygen species (Haurani and Pagano, 2007). Furthermore, 
the adventitia layer harbours a population of cells (CD34+ CD31-) able to 
differentiate into endothelial cells and participate in vessel formation (Zengin 
et al., 2006; Hu and Xu, 2011). Interestingly, a similar population of cells in the 
adventitia layer called adventitial cells with the following immunophenotype: 
CD34+ CD31- CD146-  show characteristics of stem cells, and give rise to 
MSCs in vitro when purified by FACS (Figure 3) (Corselli et al., 2010, 2012). 
Cells in the adventitia were shown to act as progenitors in vivo. For example, 
resident gli1+ adventitial cells are able to differentiate into myofibroblasts after 
injury in different organs (Kramann et al., 2015) and during kidney disease can 
contribute to calcification (Kramann et al., 2016). Similarly, PDGFRβ+ cells 
contribute to fibrosis after injury in the skeletal and cardiac muscle (Murray et 
al., 2017) . Furthermore, a subset of PDGFRβ+ cells that co-express PDGFRα 
is highly fibrotic and contributes to fatty degeneration in a model of rotator cuff 
injury (Jensen et al., 2018).   
 
Overall, these studies suggest that the adventitia layer acts as a reservoir of 
progenitors showing heterogeneity of unknown significance. The identification 
of novel markers for adventitial cells is crucial to understand the mechanisms 












Figure 3 MSC progenitors are located in capillaries and large vessels. 
Schematic of MSC progenitors in blood vessels (A) and immunofluorescence staining of 
adipose tissue (B) showing pericytes expressing CD146 in close contact with the endothelium 
stained with the Ulex europaeus lectin. Adventitial progenitor cells are located in the outermost 
layer of veins and arteries, and express CD34. DAPI staining of cell nuclei is blue. Endothelial 
cells appear yellow/green, because they express both CD34 and the receptor for Ulex. Figure 




1.2.3 Heterogeneity of perivascular progenitors and derived 
MSCs 
MSCs are heterogenous, as can be expected from cultures of total cell 
suspensions, although this high heterogeneity is reduced over time in vitro, 
allowing better protocol standardization. Indeed, clonal analysis MSC cultures 
for long periods of time has shown that diversity  is dramatically decreased 
after multiple passages (Selich et al., 2016). Moreover, MSC clones exhibit 
diverse differentiation potentials (Muraglia et al., 2000) 
 
The heterogeneity of conventional culture derived MSCs also reflects the 
diversity of their native progenitors (pericytes and adventitial cells). Analysis of 
perivascular MSCs has revealed that these cells are phenotypically and 
functionally diverse which also applies to different organs and tissues. A 
developmental hierarchy of pericytes and adventitial perivascular cells has 
been established in human adipose tissue (Hardy et al., 2017). These two cell 
types which both contribute to conventional cultured MSCs play distinct roles 
in osteogenesis in vivo (Wang et al., 2019) and probably to other cell lineages. 
Capoccia et al. (2009) found that bone marrow MSC like cells with high 
aldehyde dehydrogenase (ALDH) activity sustain better improvement of the 
ischaemic hind limb, as compared to the whole stromal cell population at low 
cell numbers. It was recently confirmed that ALDH high perivascular 
progenitors are developmentally more primitive than their ALDH low 




expressing CD10 are considerably enriched in osteogenic progenitors (Ding et 
al., 2019). 
 
1.2.4 ALDH activity as a marker of stem cells 
1.2.4.1 Aldehyde dehydrogenases family of enzymes   
Aldehyde dehydrogenases (ALDHs) are a group of enzymes that contain 19 
isoforms in the human genome (Table 1). ALDHs catalyse the oxidation of 
aldehyde substrates to their corresponding carboxylic acids.  Endogenous 
aldehydes are formed through normal metabolism of amino acids, lipids, 
alcohols and vitamins, whereas exogenous ones are derived from 
environmental agents and drugs such as cigarette smoke and cytotoxic drugs 
that are metabolized (Reviewed in Tomita et al. 2016). 
 
Among the different functions of ALDH enzymes, there is cellular detoxification 
but also gene regulation (Duester et al. 1995). There are 19 functional ALDH 
isoforms, although the ALDH1 family of enzymes is the most relevant for stem-
cell like properties. Furthermore, expression of ALDH1 family members is 
associated with drug resistance of cancer cells (Yoshida et al., 1993).  ALDH1 
enzymes are located in the cytosol and are required for the biosynthesis of 
retinoic acid (RA) (Vassalli, 2019). ALDH1A1 is highly involved in stem cell-
like properties due to its high affinity to oxidase retinaldehyde (retinal) to 
retinoic acid which is involved in proliferation and differentiation, although 




nuclear RA receptors (RARs) and retinoid X receptors (RXRs), regulating gene 
expression; consequently, RA synthesis is essential for differentiation, 
development, maintenance of organs and tissues in vertebrate animals. 
 
Table 1 ALDH Isoforms  
Isoform Preferred aldehyde Localisation 
ALDH1A1 Retinal Cytosol 
ALDH1A2 Retinal Cytosol 
ALDH1A3 Retinal Cytosol 




ALDH1L2 Unknown Unknown 
ALDH2 Acetaldehyde Mitochondria 
ALDH3A1 Aromatic, aliphatic 
aldehydes 
Cytosol/nucleus 
ALDH3A2 Fatty aldehydes Microsomes, 
Peroxisomes 
ALDH3B1 Unknown Cytosol 




ALDH5A1 Succinatesemialdehyde Mitochondria 






ALDH8A1 Retinal Cytosol 
ALDH9A1 γ-Aminobutyraldehyde Cytosol 










The retinoid signalling pathway plays important roles in normal and cancer 
stem cells (Figure 4). The regulation and function of ALDH in vitamin A (retinol) 
metabolism (Duester et al. 2003; Tomita et al. 2016) starts with retinol being 
oxidized by retinol dehydrogenases to retinal. Subsequently, retinal is oxidize 
by the ALDH1 family of enzymes, and ALDH8A1. RA can induce transcription 
of downstream effectors by entering into the nucleus to activate heterodimers 
of RAR and RXR (Tomita et al., 2016; Vassalli 2019). The ALDH1 family of 
proteins is highly active in cancer and normal stem cells making it an attractive 
marker of stem cells along with the fact that it plays functional roles such as 
self-protection, differentiation, and expansion of stem cells (Levi et al., 2009). 
However, the isolation of cells using antibodies involves the permeabilization 
of the cell membrane to allow antibodies entering the cytosol, therefore killing 
the cells. The development of the ALDEFLUOR flow cytometry assay enabled 





















Figure 4 Metabolism of retinol by ALDHs.  
Retinol in the cytosol is oxidize by retino dehydrogenases into retinal. Then ALDH1 family of 
enzymes oxidase retinal into retinoic acid (RA). RA enters the nucleus and interacts with 
intracellular receptors RARs and RXRs regulating cell proliferation, differentiation and 




1.2.4.2 Aldehyde dehydrogenases in normal and cancer stem cells 
ALDH activity has been used as a marker of normal stem cells. Indeed, 
hematopoietic and neural stem and progenitor cells have high ALDH activity 
(Armstrong et al., 2004; Corti et al., 2006). High ALDH activity has also been 
reported in adipose tissue (Estes et al., 2006) and myogenic progenitors (Jean 
et al., 2011). However, the ALDH enzymatic activity, and the expression of 
specific isoforms have been characterized mainly in cancer stem cells.   
 
High ALDH activity has been linked, in various types of cancers, to stem cell-
like features such as tumour initiating capacity, clonogenic growth, self-
renewal and drug resistance (Awad et al., 2010; van den Hoogen et al., 2010). 
Indeed, there is clinical evidence  that the remaining tumour tissue which 
survived chemotherapy contains a higher number of cancer stem cells, 
including high ALDH cells, in comparison to the original tumour tissue (Dylla et 
al., 2008; Li et al., 2008; Tanei et al., 2009).  Tumour-initiating cells with high 
ALDH activity have been described in liver (Ma et al., 2008; Dollé et al., 2012), 
ovary (Li et al., 2018), stomach (Wakamatsu et al., 2012), skin (Luo et al. 
2018), prostate (van den Hoogen et al., 2010), breast (Ginestier et al., 2007), 
brain (Choi et al., 2014), lung (Moreb et al., 2007), and bone marrow (Giordano 
et al., 2013). The presence of cells with high ALDH activity is associated with 
poor clinical outcomes (Ginestier et al., 2007; Charafe-Jauffret et al., 2010; Li 
et al., 2010; Kuroda et al., 2013). These ALDH high cells are also more 





Cancer stem cells resistant to cytotoxic drugs such as cisplatin, dacarbazine 
and doxorubicin express ALDH. These cancer cells develop resistance 
through the oxidation of specific aldehyde groups of the drug (Magni et al., 
1996). 
 
 The use of chemical inhibitors of ALDH activity sensitizes drug-resistant ALDH 
high ovarian cancer stem cells to chemotherapy (Landen et al., 2010). 
However, ALDH-dependent resistance not only affects cancer stem cells. 
Normal stem cells such as hematopoietic stem cells (HSCs) are affected by 
inhibitors of ALDH, making them more sensitive to, for example, mafosfamide, 
which is used to clear remnant cancer cells (Kaizer et al., 1985). ALDH1+ cells 
seem to contribute to resistance against chemotherapy. Moreover, ALDH1+ 
breast cancers are negative for ER (oestrogen receptor), positive for Ki-67 and 
positive for human epidermal growth factor receptor type 2 (EGFRII), and have 
lower response to adjuvant chemotherapy compared to ALDH1- breast cancer 
types (Morimoto et al., 2009). Interestingly, ALDH activity is involved in 
resistance against radiation. In particular, breast cancers with high ALDH 
activity have been shown to be HER2+ CD44+ and CD24-/low, demonstrating 





1.2.4.3 The ALDEFLUOR assay  
The ALDEFLUOR assay was first developed by Storms et al. to isolate HSCs 
with high ALDH activity (Storms et al., 1999).   In this assay, cells with high 
ALDH activity metabolize an aldehyde (BODIPY-aminoacetaldehyde, BAAA) 
into the fluorescent product (BODIPY-aminoacetate, BAA). This BAA product 
is retained inside the cells, and its accumulation can be detected by flow 
cytometry, allowing the sorting of live cells (Figure 5). Originally, the 
ALDEFLUOR assay was developed to detect the activity of the ALDH1A1 
isoform (Jones et al., 1995; Storms et al., 1999). However, other isoforms such 
as ALDH1A2, ALDH1A3 and ALDH2 have shown activity in the ALDEFLUOR 
assay (Marcato et al., 2011; Moreb et al., 2012).  
 
Many ALDH isoforms have been described to be able to oxidase the 
ALDEFLUOR substrate making it more difficult to identify specific enzymes in 
different cell types. Zhou and colleagues analysed the contribution of the 19 
ALDH isoforms to the ALDH high compartment of different cancer cell lines. 
The findings revealed that 9 ALDH isoforms are active in the ALDEFLUOR 
assay (Zhou et al., 2019). Therefore, it is essential to identify the specific ALDH 




















Figure 5 ALDEFLUOR assay principle. 
 Cells with high ALDH activity convert (BODIPY-aminoacetaldehyde, BAAA) into the fluorescent 
product (BODIPY-aminoacetate, BAA). The ALDH inhibitor, diethylaminobenzaldehyde (DEAB) is 




1.2.5 Hierarchy of perivascular cells based on their ALDH 
activity  
Perivascular cells, pericytes and adventitial cells, are involved in different 
processes such as tissue turnover, and are progenitors of MSCs in vitro. 
However, specific in vivo functions of these cell types are still unknown due to  
heterogeneity and lack of a common marker that can identify all perivascular 
cells in the human body. Adventitial cells have been described to be pericyte 
progenitors in vitro and ex vivo (Howson et al., 2005; Corselli et al., 2012). 
Furthermore, MSC-derived adventitial cells proliferate at higher rates than 
MSC-derived pericytes and have a different phenotype (Corselli et al., 2012) . 
 
Also, it has been suggested that pericytes do not behave as MSC progenitors 
in vivo in mice (Guimarães-Camboa et al., 2017) whereas it is well documented 
that adventitial progenitors can proliferate and contribute to fibrosis and 
calcification, and probably to muscle cells (Kramann et al., 2015, 2016; Murray 
et al., 2017). More recently, adventitial cells have been described to be more 
primitive than pericytes (Hardy et al., 2017). Both types of perivascular cells 
were isolated based on their high or low ALDH activity and network analysis of 
single cells was performed. The resulting analysis of 500 genes in every 
population of cells revealed a hierarchy of perivascular cells (Figure 6 ): ALDH 
high ADV (most primitive); ALDH low ADV; ALDH high PC; ALDH low PC (least 
primitive). Moreover, adventitial cells showed an evenly distribution of cells 
extending from low to high ALDH, whereas pericytes mostly showed low ALDH 




correlated with stem cell properties, suggesting that a higher percentage of 
adventitial cells show stem cell-like phenotypes as compared to pericytes 
(Figure 6). Therefore, adventitial cells with high ALDH activity may contain 
cells with stem cell properties.  
 
However, a comprehensive characterisation of ALDH subsets of perivascular 
cells in vitro and in vivo has not been done.  In this thesis I aimed to 
characterise the ALDH high subset of adventitial cells to assess their in vitro 



















Figure 6. Proposed hierarchy of perivascular cells.  
Proposed model of hierarchy of perivascular cells where adventitial cells 






















2.1 Tissue Procurement  
2.1.1 Human adipose tissue  
Adipose tissue was collected from human female volunteers undergoing 
cosmetic liposuction. Informed consent from the donor was signed, and ethical 
permission was granted by the South East Scotland Research Ethics 
committee (Ref number: 16/SS/0103) 
2.1.2 Human brain tissue  
Brain tissue (glioblastoma) was kindly donated by Dr. Paul Brennan from the 
University of Edinburgh. The ethical permission number is: 15/ES/0094 
2.1.3 Human foetal heart and skeletal muscle 
These samples were obtained by our laboratory member Joan Casamitjana 
from the Center for Vascular Sciences 
2.1.4 Human uterus  
These samples were kindly donated by Professor Hilary Critchley from the 
Center for Reproductive Health (CRH) of the University of Edinburgh. 
  
2.2 Mouse models  
2.2.1 Rotator cuff injury  
2.2.1.1 C7BL/6 background mice 
The tissue sections of injured rotator cuff muscle in wild type mice were kindly 





2.2.1.2 Surgical procedure (performed by collaborators at UCLA) 
A massive rotator cuff tear was done by making a 1-cm skin incision over the 
right glenohumeral joint. Subsequently, the deltoid fibers were split directly 
posterior to the deltoid tuberosity longitudinally. The supraspinatus and 
infraspinatus tendons were dissected, and the distal was resected 5 mm of 
each tendon to prevent scar formation to the humerus. Then, the 
suprascapular nerve was identified and cut. Last, the deltoid muscle was 
closed. 
 
2.2.2 Mouse heart tissue  
Mouse cardiac tissue was kindly provided by Dr. Gillian Gray from the Center 
for Vascular Science (CVS) of the University of Edinburgh,.  
 
2.3 Tissue processing for cell isolation 
2.3.1 Human white adipose tissue dissociation and flow 
cytometry  
Human adipose tissue was collected from surgical procedures in sterile 
containers and stored at 4°C in PBS supplemented with 5% (v/v) fetal calf 
serum (FCS). The tissue was next treated according to our established 
protocol (Crisan et al., 2008; Corselli et al., 2012). In short, I minced the tissue 




centrifuged at 448 Relative Centrifugal Force (RCF) for 10 min at room 
temperature (RT). This allowed the separation of cells into 3 phases, oil, 
stromal vascular fraction (SVF) containing my cells of interest and debris. I 
next aspirated the oil and debris, and suspended the cell pellet in PBS 
supplemented with 2% (v/v) FCS . Approximately, 25ml of human adipose 
tissue was mixed with 25ml of FACS buffer and spun down at 2000 rpm for 10 
min at RT. The supernatant was removed and 25ml of digestion solution 
(1mg/ml - collagenase II-S in DMEM) was added to the tube; I next transferred 
the tubes into a shaking water bath at 37°C, 4 RCF for 45 min.  
The digested tissue was filtered using strainers (400 µm,100 µm, 70 µm and 
40 µm pore size)  and washed with PBS/2% FCS (v/v), then incubated with 
red blood cell lysis buffer (ammonium chloride/Tris base (9:1 ratio), pH 7.65) 
for 10 min at RT. After incubation, the cells were washed and stained with the 
ALDEFLUOR kit for 45 min at 37°C according to manufacturer’s instructions 
(StemCell technologies).  Cells were then resuspended in ALDEFLUOR buffer 
and stained with fluorescent antibodies (Table 2) for 20 min on ice. Pericytes 
and adventitial cells were sorted using a BD FACS FUSION sorter based on 
the marker combinations previously described (Crisan et al., 2008; Corselli et 











Table 2 Antibodies used for cell sorting of perivascular cells based on 
ALDH activity 
Marker Fluorochrome Supplier Dilution 
CD146 BV711 BD Horizon 
563186 
1:100 
CD34 PE BD Horizon  
555822 
1:100 
CD31 V450 BD Horizon 
561653 
1:400 
CD45 V450 BD Horizon 
560367 
1:400 



















2.3.2 Human brain tissue preparation and flow cytometry  
Human malignant brain tissue (glioblastoma) was collected from surgical 
procedures in sterile containers and stored at 4°C in PBS supplemented with 
5% (v/v) FCS. The tissue was next treated according to our established 
protocol (Crisan et al., 2008; Corselli et al., 2012). Cells were washed and 
stained with the ALDEFLUOR kit for 45 min at 37°C according to 
manufacturer’s instructions (StemCell technologies).  Cells were then 
resuspended in ALDEFLUOR buffer and stained with fluorescent antibodies 
(Table 3) for 20 min on ice. Pericytes and adventitial cells were analysed using 
a BD Fortessa cell analyser based on marker combinations previously 
described (Crisan et al., 2008; Corselli et al., 2012; Hardy et al., 2017). CD56 
antibody was added to the combination of antibodies to discard neuron which 












Table 3 Antibodies used to analyse brain tissue (GBM) 
Marker Fluorochrome Supplier Dilution 
CD146 BV711 BD Horizon 
563186 
1:100 
CD34 PE BD Horizon  
555822 
1:100 
CD31 V450 BD Horizon 
561653 
1:400 
CD45 V450 BD Horizon 
560367 
1:400 
CD56 PECy7 BD Horizon  
557747 
1:100 



















2.3.3 Quantification of ALDH activity in flow cytometry  
In order to quantify ALDH activity, the mean fluorescent intensity (MFI) of the 
ALDH high compartment (channel 488 filter) was measured in each type of 
perivascular cells. Subsequently, the value of the ALDH low remaining 
compartment was subtracted to obtain a comparable value between the two 
cell types. 
 
2.4 Cell culture  
2.4.1 Standard cell culture  
Sorted perivascular cells were seeded into culture plates at a density of 20000 
cells/cm2 and cultured (37 °C, 5% CO2 ) in Endothelial Cell Growth Medium 
(EGM-2 Bulletkit- Lonza) in plates pre-coated with 0.1% gelatin. Once cells 
were confluent, we passaged them into DMEM, high glucose, GlutaMAX™ 
supplement (Sigma Aldrich), 20% FCS. On subsequent passages, the cells 
were re-plated in larger wells with the appropriate volume of medium (Table 













Table 4 Culture plates and flasks used for perivascular cells 
Well plate Surface Area 
(cm2) 
Working Volume of Medium 
(ml) 
96-well plate 0.32 0.370 
48-well plate 0.75 0.5-0.8 
24-well plate 2 0.8-1 
12-well plate 3.8 1.5-2.2 
6-well plate 9.6 2.5-3 
25 cm2 flask 
(T25) 
25 5 











2.4.2 Differentiation into mesodermal cell lineages  
For adipogenic differentiation, cells were seeded at a density of 20000 
cells/cm2 and incubated at 37°C overnight to allow cells to attach.  Next day, 
media was switched to DMEM, 10% FSC,1 μM dexamethasone, 0.5 mM 
isobutylmethylxanthine, 200 μM indomethacine, and 10 μM insulin (all from 
Sigma-Aldrich). Cells were fixed with 4% PFA (paraformaldehyde) at RT at 
different time points (14, 21 and 28 days), washed with 70% ethanol and 
incubated with Oil red O (Sigma- Aldrich) for 15 min at RT for detection of 
lipids.  
 
For osteogenic differentiation, cells were seeded at a density of 20000 
cells/cm2 and incubated at 37°C overnight to allow cells to attach. Next day, 
media were switched to DMEM,10% FSC, 0.1 μM dexamethasone, 50 μM 
ascorbate-2-phosphate, and 10 mM β-glycerophosphate (all from Sigma-
Aldrich). Cells were fixed with 4% PFA at RT at different time points (14, 21 
and 28 days), washed with milliQ water and incubated in alizarin red (Sigma-
Aldrich) solution for 15 min at RT for detection of calcium.  
 
2.4.3 Quantification of differentiation  
For osteogenesis, 10% acetic acid was added to alizarin red-stained cells and 
incubated with shaking for 30 min. Next, the acid was taken along with the cells 
by scraping the bottom of the well and transferred into a 1.5 ml Eppendorf tube, 




min. The tubes were centrifuged for 10 min at 21952 RCF, next 500ul were 
taken into a new tube to which 200ul of ammonium hydroxide was added. After 
mixing the tubes, 50ul were transferred into a well of a 96 well plate, then 
absorbance at 405nm was measured in a FLUOstar Omega Microplate 
Reader. 
 
2.4.4 Angiogenesis assay in vitro  
Subsets of ALDH adventitial cells and human umbilical vein endothelial cells 
(HUVEC) were used to analyse angiogenesis support.  10ul of matrigel (BD 
Membrane Matrix, BD Biosciences) were seeded into 96-well plates (Ibidi) and 
allowed to set for at least 20 min at 37°C. After gelation, cells were suspended 
in EGM-2 and then seeded into the wells with matrigel. The ratio used was 
10:1 HUVEC to perivascular cells. Images were taken after 6 h, once the tubes 
were formed. Tube formation was analysed using angiogenesis plugin of 
ImageJ, Fiji. 
 
2.4.5 Cell proliferation assay  
Cells were seeded at a density of 4210 cells/cm2 with 3 technical repeats per 





2.4.6 AlamarBlue assay of cell viability 
Cells were plated at 5000 cells per well in clear flat bottomed 96 well plates 
(Corning) and allowed to adhere. After administration of treatments, 
AlamarBlue cell viability dye (Invitrogen) was added to culture medium at a 
ratio of 1:10. Fluorescence was measured on a GloMax Explorer spectrometer 
(Promega, Southampton, UK) at 1-hr intervals to ensure a linear rate of 
change, and the three h time point used for analysis. 
Fluorescence values for cell containing wells were normalized to zero based 
on readings from cell free wells containing AlamarBlue reagent in medium. 
 
2.5 RNA sequencing 
RNA sequencing was performed in University of California Los Angeles 
(UCLA) by Dr Reef Hardy. Sub-populations of ALDH low and high perivascular 
cells from 3 healthy donors (age range 35-63 years; BMI range:21.1 – 32.0) 
were sorted into cell lysis solution and purified using the Qiagen RNeasy Micro 
kit (Qiagen). cDNA for each subpopulation was prepared using the NuGen's 
Ovation RNA‐Seq System V2 kit from approximately 100 ng of RNA pooled 
from 2 or 3 donors. High throughput sequencing was conducted on an Illumina 
Hiseq 2000 platform. Samples were normalized by RPMK (reads per kilobase 
of exon per million mapped reads) which takes into account both library size 
and gene length in within‐sample comparisons. Similar numbers of reads 





RNA Sequencing for cultured cells was done after 3 passages. Adventitial cells 
and pericytes were stained with fluorescent antibodies to CD31, CD45, CD146 
and CD34. All adventitial cells were collected as they showed no expression 
of the markers; in the case of pericytes, only those expressing CD146 were 
isolated for RNA sequencing.  
 I performed principal component analysis (PCA) and volcano plot using 
PARTEK software with the raw FASTQ files. Heatmaps and further analysis 
ere performed using the package “pheatmap” on Rstudio.  
 
2.6 Histology  
2.6.1 Immunofluorescence  
Frozen sections were fixed in acetone: methanol (1:1) for 10 min prior staining.  
Paraffin sections were dewaxed by sequential incubations with xylene for 10 
min, 100% ethanol for 1 min, 95% ethanol for 1 min, 80% ethanol for 1 min 
and 70% ethanol for 1 min. After dewaxing, slides went through an antigen 
retrieval step by boiling the slides in citrate buffer (0.05% Tween, pH 6) for 5 
min.  
After fixation/dewaxing, slides were washed 3 times with PBS for 10 min then 
blocked with 10% goat serum for 1 h at RT. Sections were then incubated with 
primary antibodies (Table 5) overnight at 4°C. Next day, slides were washed 3 
times with PBS for 1 min, then secondary antibodies (Table 6 ) were added 




times with PBS for 10 min and mounted with mounting medium containing 
DAPI for nucleus staining. 
For intracellular staining, tissue sections were incubated with 0.5% triton-X-
100 in PBS for 10 min and washed 2X with PBS for 10 min prior to blocking 
with goat serum. 
If the primary antibody was biotinylated, a step of blocking with avidin and 
biotin was performed prior to blocking with serum. Tissue sections were 




























NG2 Mouse Human Pericytes Millipore 
AB5320 
1:100 
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Table 6 Secondary antibodies used to detect primary antibodies 
Colour Species 
raised 
Reactivity Supplier Dilution 
Alexa Fluor 488 
Streptavidin 
 Biotin Life 
technologies 
1:300 
Alexa Fluor 555 Goat Mouse Life 
technologies 
1:300 
Alexa Fluor 647 Goat  Rabbit  Life 
technologies 
1:300 






2.6.2 Flow cytometry analysis of cultured cells 
Cells were detached with 0.25% trypsin EDTA and washed with PBS 
supplemented with 2% FCS. Then cells were stained with conjugated 
antibodies for mesenchymal stromal/stem cell markers: CD44,CD105 ,CD90 
and CD73 (Table 7).  
Cells were analysed using flow cytometry by passing the cells through a 5 laser 





Table 7 Antibodies used for analysis of MSC markers 
Marker Fluorochrome Supplier Dilution 
CD73 PerCP Cy5.5 BD Pharmingen 
561260 
1:100 




CD90 APC BD Pharmingen 
559869 
1:1000 





Images were taken using a wide field Zeiss Observer microscope with a 
Colibri7 LED light source (Zeiss). A Hamamatsu Flash 4.0 v3 camera 
(Hamamatsu Photonics) was used for monochromatic fluorescent and 
brightfield images and an inverted widefield Live Imaging Nikon TiE for 
angiogenesis assays. Magnifications of 10X, 20X and 63X were used to take 
images.  
2.6.4 Statistical analysis  
Data were analysed using GraphPad Prism software. Number of biological 
replicates is indicated as (n). Every biological replicate has 3 technical 
replicate. Shapiro- Wilk normality test was performed in all data sets. I used 




For more than 2 groups analysed, I used One-way Anova with Tukey post-test 
























Chapter 3 CHARACTERISATION OF 
MESENCHYMAL STEM CELL 
IDENTITY OF ALDH SUBSET OF 










3.1 Introduction  
In the last decade, blood vessels were identified to harbour progenitors of 
mesenchymal stem/stromal cells (MSCs), which reflects the isolation of MSCs 
from every vascularized organ (Nombela-Arrieta et al., 2011) . Two 
populations of perivascular cells give rise to MSCs: pericytes (CD146+ CD34- 
CD31-  CD45-) embedded in the basement membrane in close contact with 
endothelial cells, and adventitial cells (CD146- CD34+ CD31- CD45-), found 
in the adventitial layer of large vessels  give rise to MSCs in vitro (Crisan et al., 
2008; Corselli et al., 2012). 
Subsets of perivascular cells have been characterised in vitro once they 
transition into MSCs.  The study of subsets is of therapeutic importance as 
specific subsets of perivascular cells have different mesodermal differentiation 
potential. For example, CD10+ and PDGFRα+ subsets of perivascular cells 
show higher osteogenic potential (Ding et al., 2019; Wang et al., 2019) which 
may be beneficial for bone repair. PDGFRβ+ PDGFRα- perivascular cells are 
myogenic in vivo and in vitro (Jensen et al., 2018) suggesting higher 
regeneration potential for skeletal muscle injury.  MSCs with high ALDH activity 
have been previously described (Sherman et al., 2017; Najar et al., 2018). 
However, the studies were performed after in vitro expanded MSCs. Here, I 
characterised the MSC identity and the differentiation potential into osteogenic 
and adipogenic cell lineages of native adventitial cells with high ALDH activity 





3.2 Hypothesis and aims  
3.2.1 Hypothesis  
“High ALDH activity identifies subsets of adventitial cells that give rise to 
MSCs with higher osteogenic, adipogenic and angiogenic support potential” 
 
3.2.2 Aims  
• To sort and expand subsets of adventitial cells based on ALDH activity  
• To characterise differentiation potential (osteogenesis and 
adipogenesis) in vitro of ALDH subsets 
 
• Characterisation of expression of MSC markers on ALDH subsets  
 
• To determine the proliferation capacity and the angiogenesis support 








3.3 Results  
3.3.1 The stromal vascular fraction is enriched in adventitial 
cells 
Perivascular cells, pericytes and adventitial cells, are present in human tissues 
in different frequencies depending on the types of vessels present. Adipose 
tissue is highly vascularized and is a great source of mesenchymal stem cells. 
However, the contribution of each type of perivascular cell to the stromal 
vascular fraction is not known. 
 
In order to assess percentages of perivascular cells in adipose tissue, I used 
flow cytometry and quantified these cell types in the live compartment. Since 
the stromal vascular fraction is comprised of several types of cells including 
hematopoietic cells, endothelial cells, fibroblasts, perivascular cells and other 
cell types, we discarded these cells  using negative selection of CD31, CD45 
and CD56 positive cells (Figure 7,A) to remove endothelial cells and 
hematopoietic cells. Pericytes and adventitial cells were then identified by the 
expression of CD146 and CD34, respectively. Adventitial cells comprised 
around 80% of the live cells (after negative selection) whereas pericytes   
















Figure 7 Quantification of the perivascular cell compartment in the stromal vascular 
fraction. 
A. Perivascular cells are sorted as live single cells, negative for CD31,CD45,CD56. Pericytes 
are CD146+CD34- and adventitial cells CD146-CD34+. B. Numbers of pericytes and 
adventitial cells in the stromal vascular fraction show a higher percentage of adventitial cells 
than pericytes.  Unpaired t-test with Welch’s correction was used. Data are shown as mean ± 




3.3.2 Perivascular cells can be sorted according to ALDH 
activity  
 
In order to sort cells with high ALDH activity from each type of perivascular 
cells, we performed the ALDEFLUOR assay. This involved the use of a reagent 
that is metabolised by ALDH enzymes and DEAB (N,N-
diethylaminobenzaldehyde) inhibitor to gate the ALDH high population (Figure 
8,B&C). The low ALDH population was gated at the other extreme of the plot 
to avoid contamination by cells with higher ALDH activity. 
 
I found that 16.5 % (± 3.076, n=6) and 14.53 %(± 5.418, n=6) of adventitial 
cells and pericytes respectively were ALDH high (Figure 8). Therefore, the 
percentages of ALDH high cells in both types of perivascular cells are similar. 
However, adventitial cells with high ALDH activity are in higher numbers in the 
SVF since adventitial cells comprise 80% of the cells. In addition, ALDH activity 
is correlated with a primitive phenotype, therefore it is important to investigate 








Figure 8 Human perivascular cell isolation from white adipose tissue according to their 
ALDH activity 
A. Perivascular cells are identified as live single cells, negative for CD31,CD45,CD56. 
Adventitial cells and pericytes were gated based on the expression of CD34 and CD146. B&C.  
ALDH high adventitial cells and pericytes were then gated based on ALDH activity and the 







3.3.3 ALDH subpopulations of adventitial cells express MSC 
markers and can differentiate into adipocytes and 
osteocytes 
Once cells were expanded in culture and transitioned into mesenchymal 
stem/stromal cells (MSCs)I performed standard experiments to characterise 
MSCs in ALDH subsets in vitro (Chamberlain et al., 2007) that include MSC 
marker expression analysis by flow cytometry (CD73,CD105,CD90, CD44) 
and functional in vitro assays to test their potential to differentiate into 
mesodermal cell lineages. Since it is also well documented that some 
subpopulations of MSCs in culture have different potentials to differentiate into 
osteogenic or adipogenic lineages, differentiation capacity was also quantified.  
 
MSC markers 
Cells expanded in culture were stained with fluorescent antibodies and 
analysed for the expression of typical MSC markers. Data were analysed using 
FlowJo software. ALDH low and high subsets of adventitial cells expressed 
CD73, CD105, CD90 and CD44 at the same levels as typical MSCs isolated 
from adipose tissue (Figure 9). 
 
Osteogenic differentiation  
Cells undergoing osteogenic differentiation accumulate calcium deposits that 




extraction of alizarin from the calcium deposits with acetic acid and subsequent 
analysis using spectrophotometry (Figure 10,B).  
 
Adipose differentiation  
Cells undergoing adipose differentiation change their morphology and form 
intra-cytoplasmic lipid droplets. These lipid deposits are stained with Oil red O 
.  Since accumulation of intra-cytoplasmic lipids is proportional to differentiation 
capacity, we quantified differentiation by measuring the area covered by lipid 
droplets stained with Oil Red O (Figure 11,B).  
 
In 4 independent experiments, I found no significant differences between 
ALDH high and low adventitial cells with respect to capacity to differentiate 
towards adipocytes or osteocytes, although there seems to be a trend 
suggesting that ALDH high adventitial cells are more osteogenic at day 21 and 
less adipogenic at day 28. 
 
In conclusion, these studies confirmed the MSC identity of the ALDH subsets. 
However, quantification of  cell differentiation shows that ALDH subsets of 












Figure 9 ALDH sub-populations of adventitial cells express MSC markers in vitro. 
 Sub-populations of adventitial cells were sorted according to their ALDH activity and put in 
culture for 3 weeks. Cells were then stained with antibodies to the canonical MSC markers 
CD73,CD105,CD90 and CD44. Typical MSCs isolated from adipose tissue were used as 











Figure 10 Osteogenic differentiation of subsets of perivascular cells. 
 Cultured  perivascular cells were put under osteogenic differentiation conditions, stained and 
quantified at different time points. A. Differentiation capacity seems to be donor dependent. B. 
Quantification of osteogenesis at different time points for ALDH subsets and whole population 
of adventitial cells and MSCs as control. Time points represent days post-induction. Two-Way 














Figure 11 Adipogenic differentiation of subsets of perivascular cells. 
 Cultured  perivascular cells were put under adipogenic differentiation conditions, stained and 
the area covered by adipocytes was quantified after 28 days. A. Differentiation capacity seems 
to be donor dependent. B. Quantification of adipogenesis for ALDH subsets and whole 
population of adventitial cells and MSCs as control.  One-Way ANOVA with Tukey post test. 




3.3.4 There is no difference in proliferation and metabolic 
activity between ALDH subsets of adventitial cells  
The proliferation rate of a given cell type may give us information about their 
behaviour in their niche. Stem cells are considered to be quiescent and divide 
at low rate. However, once in culture, this may change since their environment 
has been drastically modified. 
 
In order to assess the proliferation rate of our subsets of adventitial cells, I 
used two methods. The first one by seeding a given number of cells and 
counting every 3 days to calculate differences in cell numbers. The other 
method was by using AlamarBlue, a reagent that is oxidized by the cell and is 
correlated with metabolic health and indirectly with cell proliferation. 
 
There was no significant difference in proliferation rate between the different 
ALDH subsets, and also when compared to the whole population of adventitial 
cells and MSCs (Figure 12). Similar results were found using AlamarBlue This 
means that cells, after in vitro expansion, become similar. However, in the 









Figure 12 Proliferation assay and AlamarBlue activity. 
A. Cells were seeded at a known density and counted every 3 days to analyse the proliferation rate 
of subsets of adventitial cells, and also common MSCs as control. B. AlamarBlue is used to 
indirectly analyse the proliferation and metabolic health of the cells. The different subsets were 
seeded with alamarblue reagent and the fluorescence intensity was measured every hour. Two-




3.3.5 ALDH subsets of adventitial cells modify the vascular 
network formation by HUVEC in vitro  
Angiogenesis takes place during normal tissue development and also after 
injury during wound healing. This process is associated with different 
pathological conditions including autoimmune disorders, atherosclerosis, and 
cancer, among others. Due to the involvement of angiogenesis in various 
diseases, better understanding of this process is crucial to design therapeutics.  
 
Perivascular cells are involved in angiogenesis in vivo, and MSCs derived from 
perivascular cells have been already used to promote angiogenesis in different 
disease models. Hence, we investigated whether ALDH high adventitial cells 
are different than ALDH low counterparts when co-cultured with human 
umbilical vein endothelial cells (HUVEC). 
 
To determine the angiogenesis support by ALDH subsets of adventitial cells, I 
co-cultured ALDH subsets with HUVEC for a period of six hours once tubes 
were formed (4 biological replicates with 3 technical replicates each).  
 
To quantify angiogenic support by ALDH subsets, pictures of the co-cultures 
after tubes were formed were taken and analysed using the angiogenesis 
plugin of ImageJ. This plugin extracts a binary image of the tubes which is then 
used to count nodes, length, branches, junctions, extremities, among others 




We found that 2 out of the 8 features analysed were different between the 
ALDH subsets and HUVEC alone (Figure 14).  The number of nodes was 
higher in ALDH low adventitial cells when compared to ALDH high adventitial 
cells and HUVEC.  On the other hand, the number of extremities was lower in 
co-cultures with subsets of ALDH adventitial cells than HUVEC.  
 
In conclusion, I found that ALDH subsets of adventitial cells are similar in 
regard to angiogenic support in vitro. However, to a certain extent both 
perivascular cells modified the vascular network. Moreover, whether the cells 








Figure 13 Analysis of tube formation on ImageJ with the angiogenesis function 
After 6 hours of co-culture of perivascular cells with HUVEC, images of the vascular network 
were taken and analysed. Then, images are processed on ImageJ with the angiogenesis 
plugin. The vascular network is analysed and a binary tree is created, and analysed with the 






Figure 14 Results of tube formation on ImageJ with angiogenesis function 
After 6 hours of co-culture of perivascular cells with HUVEC, images of the vascular network were 
taken and analysed. Images were are processed on ImageJ and a binary tree is created, and 
analyse with the angiogenesis function of ImageJ to quantify, nodes, branching and junctions. 






3.4 Discussion  
3.4.1 Mesenchymal stem cell identity and functionality 
analysis: differentiation potential and angiogenesis 
support   
Once the characterization of the ALDH activity on our fresh and cultured 
subsets of adventitial cells was performed, I characterized the subsets with the 
typical assays that define an MSC. 
 
Mesenchymal stem cells or MSCs are well known to express CD44,CD73, 
CD90, and CD105 (Chamberlain et al., 2007). These canonical MSC markers 
are a hallmark to identify the MSC phenotype. Indeed, ALDH high and low 
adventitial cells express the canonical MSC markers. However, in order to 
properly identify our cells as MSCs, differentiation assays into mesodermal cell 
lineages were required.  
 
Two mesodermal cell lineages were analysed in the ALDH subsets of 
adventitial cells: bone and fat. These two lineages are of high interest for our 
laboratories since the group is involved in the study of the normal and 
pathologic musculoskeletal system. ALDH high MSCs were previously 
described to be more osteogenic, adipogenic, and chondrogenic than the 
ALDH low compartment (Sherman et al., 2017). However, this was only 





Quantification of osteogenesis and adipogenesis in our ALDH subsets of 
adventitial cells showed no statistical difference. However, donor variation was 
a main factor in this result.  ALDH high derived cells from two out of four donors  
were highly osteogenic, whereas the other two donors show less differentiation 
potential. The medical history of the patients is not accessible, thus unknown 
factors may affect the differentiation capacity of these cells. Indeed, it has been 
reported that smoking and drug use affects MSC differentiation potential 
(Greenberg et al., 2017). Therefore, stratification of donors by age and medical 
history would greatly improve the study. 
 
Cell therapy requires high number of  cells, usually between 1-2 million per kg 
of body weight in humans, with optimal metabolic fitness (Galipeau and 
Sensébé 2018; Katarzyna et al. 2019)  Therefore, the proliferation rate and 
metabolic health of ALDH subsets of adventitial cells were analysed. The 
results showed that the subsets, including the controls (MSC and ADV), are 
similar after in vitro expansion in terms of proliferation. Taken together, all the 
in vitro analysis suggests that after expansion ALDH subsets of adventitial 
cells are similar in phenotype and differentiation potential. It appears that after 
a certain number of passages primary cells become a homogenous 
population. Indeed, it has been reported that after 11 passages the MSC 
population is derived from just a few clones from the initial heterogeneous 
population, and this selection occurs at early passages (Selich et al., 2016). 
However, other subsets of in vitro expanded perivascular cells have shown 




of perivascular cells expressing PDGFRα and CD10 perivascular cells show a 
higher osteogenic differentiation potential in vitro compared to their negative 
counterpart (Ding et al. 2019; Wang et al. 2019). These contrasting results 
may be because the ALDH high compartment of cells contains other subsets 
including PDGFRα+ and CD10+ cells. Indeed, mRNA levels of CD10, 
PDGFRα (osteogenic markers) and CD107a (novel adipogenic marker) are 




Figure 15 Markers of differentiation potential in perivascular cells 
RNA sequencing performed in ALDH low and high compartments of adventitial cells reveals 






Finally, MSCs have been used to prevent fibrosis and re-establish blood flow 
in models of myocardial infarction (Amado et al., 2005; Jeong et al., 2018; 
Madigan and Atoui, 2018) and hind limb ischemia (Capoccia et al., 2009). 
These studies showed that MSCs increase angiogenesis by the release of 
factors such as VEGF (Sorrell et al., 2009). However, this was performed using 
expanded MSCs that originate from the heterogeneous stroma. Moreover, 
data from our laboratories (Gonzalez et al., in preparation) showed that 
pericytes and adventitial cells have different abilities to induce angiogenesis. 
Following this rationale, I performed in vitro angiogenesis  using HUVEC co-
culture with ALDH subsets of adventitial cells. It was found that these cells do 
not change the vascular network after tubes are formed. However, the number 
of nodes and extremities significantly changed compared to the control 
HUVEC alone culture. (Figure 14). A possible reason for this similarity between 
the ALDH subsets is the loss of heterogeneity during in vitro expansion. ALDH 
high cells have been used in a model of hind limb ischemia with positive 
results. However, this study was performed using freshly sorted cells from 
bone marrow (Capoccia et al., 2009). As it was shown in this thesis, our ALDH 
subsets of cells upon  in vitro expansion become phenotypically similar which 
may explain why ALDH high cells are not as osteogenic, adipogenic and 
angiogenic as previously reported (Capoccia et al., 2009; Sherman et al., 
2017; Najar et al., 2018). Najar et al and Sherman et al used ALDH high 
cultured MSCs. However, they performed mRNA analysis right after isolation 
and the angiogenesis assay was performed in vivo making it difficult to link our 




progenitors showing that even at low number ALDH high cells were better at 
inducing vascularisation compared to either the ALDH low subset or the whole 
population of bone marrow cells at high numbers (Figure 16). Indeed the use 
of uncultured cells has been proposed (James and Péault 2019; Murray and 
Péault 2015). The use of cultured cells is time consuming and increases the 
likelihood of tumorigenicity and genetic instability. Moreover, MSCs after 
consecutive passages decrease the capacity to differentiate into mesodermal 
lineages, undergo senescence and the expression of adhesion molecules and 
chemokines, along with the ability to respond to soluble factors is reduced 
(Muraglia et al., 2000; Zuk et al., 2002; Baxter et al., 2004; Dahl et al., 2008; 



















Figure 16 Capillary density after ALDH high cell treatment in mouse hind limb ischemia 
Tail vein injection of different groups of uncultured cells after right femoral artery ligation was 
performed to analyse the recovery induced by different subsets of cells derived from bone 
marrow. PBS, MNC=Mononuclear cells, ALDH low cells, ALDH high cells were injected. 
ALDH high cells showed an increase of perfusion compared to the other cell types even at 
much lower numbers. A. mice injected with PBS. B. Mice treated with mononuclear cells 
(whole population). C. Mice treated with ALDH low cells. D. Mice treated with ALDH high 





To our knowledge a study comparing the use of uncultured MSC progenitor 
cells and their in vitro counterpart has not been performed. Nevertheless, our 
data and other reports suggest that uncultured cells are a better option for cell 
therapy. Another variation of uncultured cell therapy is the use of micro-
fragmented fat containing MSC progenitors that is already on the market under 
the name of Lipogems. It was shown that mechanically processed fat 
conserves the perivascular niche that may help improve regeneration 
compared to enzymatically digested tissue by the increased release of soluble 
factors (Vezzani et al., 2018). 
 
 In conclusion, based on our data along with previous reports, the use of 
uncultured cells would be a better approach to improve the clinical outcome, 
although the number of cells obtained is much lower than in culture conditions. 
Therefore, not applicable to all protocols of cell therapy. The dosage of cells is 
still under study and is dependent on condition being treated. For example, 
Schuleri et al. directly injected autologous MSCs into pig hearts with reduction 
of the infarct  size with a high dose (200 million cells) compared to low dose 
(20 million cells) (Schuleri et al., 2009). In contrast to this result, Hashemi et 
al. showed that lower dose of MSCs (24 and 240 million cells) exhibited a 
significant decrease in infarct size, whereas the higher dose group of MSCs 
(400 million cells) did not (Hashemi et al., 2007). Thus, high or low cell dose 












Chapter 4 CHARACTERISATION OF ALDH 
ACTIVITY IN WHITE ADIPOSE 










Perivascular cells display high heterogeneity. Indeed, various groups have 
identified sub-populations of perivascular cells involved in different pathologies 
such as vessel remodelling and organ fibrosis (Stenmark et al., 2006; Di Carlo 
and Peduto, 2018) . Expression of Gli1 marks profibrotic perivascular cells in 
the kidney and heart (Kramann et al. 2015), bone marrow (Schneider et al., 
2017). Lineage tracing experiments showed that Gli1+ cells differentiate into 
smooth muscle cells, migrate to the intima and contribute to vessel calcification 
in chronic kidney disease (Kramann et al., 2016). Members of our laboratory 
have also identified MSC-like cells expressing PDGFRβ that contribute to 
fibrosis in the skeletal muscle and heart (Murray et al., 2017). In addition, a 
subset of PDGFRβ+ cells co-expressing PDGFRα was identified as a driver of 
fibrosis (Jensen et al., 2018). Since perivascular cells are heterogeneous, it 
remains unclear whether specific subsets play distinct functions, and if these 
are tissue-dependent and how they are developmentally linked. For example 
pericytes in the developing kidney express renin and produce it in vitro 
(Stefanska et al., 2016), and it has been suggested that expression of VEGFR2 
in adventitial cells identifies a population that give rise to cardiomyocytes 
(Mekala et al., 2018).  
 
ALDH activity is described as a stem cell marker in different types of cancer 
and normal tissues (Burger et al., 2009; Tomita et al., 2016). Hardy et al. 




ALDH activity and performed network analysis of gene expression by single 
cells (Hardy et al., 2017). The results showed that adventitial cells have a more 
primitive phenotype than pericytes, and that adventitial cells with high ALDH 
activity are the most primitive of perivascular cells.  ALDH activity has been 
widely used to isolate normal and cancer stem cells from different tissues using 
the ALDEFLUOR assay (Burger et al., 2009; Schuurhuis et al., 2013; Ohmura-
Kakutani et al., 2014; Raha et al., 2014; Luo et al., 2018). However, there has 
been no characterisation of perivascular cells with differential ALDH activity. 
Therefore, I sought to study the ALDH high compartment of adventitial cells. 
High ALDH activity in adventitial cells indicates the existence of a subsets of 
primitive progenitors subset of adventitial cells that may play a role in 
regeneration and vessel remodelling. In order to characterise this subset of 
adventitial cells, in vitro studies as well as transcriptional analysis were 
performed. Moreover, I link the findings in normal tissue to cancer, and finally 









4.2 Hypothesis and aims  
4.2.1 Hypothesis 
“High ALDH activity marks a stem-like cell population in the adventitial 
layer of large vessels” 
ALDH activity is a stem cell marker in different types of tissues and cancers, 
and it has been shown that adventitial cells contain a population with high 
activity of ALDH enzymes. However, this ALDH high cell compartment has not 
been characterized in the native niche, neither its potential as mesenchymal 
progenitors in vitro. 
 
4.2.2 Aims 
• To sequence RNA on freshly FACS sorted ALDH perivascular cell 
subsets 
• To analyse expression of known markers for fibrosis, the PDGF 
receptors, in the ALDH cell compartments using flow cytometry  
• To identify subpopulations of adventitial cells and pericytes using 
immunofluorescence in different human tissues based on novel 
markers found by RNAseq.  
• To investigate by RNA sequencing transcriptomic changes in ALDH 









4.3 Results  
4.3.1 Adventitial cells have higher ALDH activity than 
pericytes 
In order to quantify ALDH activity, the mean fluorescence intensity (MFI) of the 
ALDH channel (488 nm filter) was measured in each type of perivascular cells. 
Subsequently, the fluorescence intensity of the remaining ALDH low 
compartment was subtracted to obtain a comparable value between the two 
cell types. Adventitial cells show higher ALDH activity compared to pericytes 
(pericytes, 4648 ± 448.6 and adventitial cells, 60639 ± 8130, n=5) (Figure 17, 
B) providing more evidence that adventitial cells have a more stem cell-like 
phenotype than pericytes. Nevertheless, the percentage of  ALDH high cells is 
similar (Figure 17,A).  
 
As perivascular cells become MSCs in vitro, we then investigated how culture 
conditions changed the ALDH activity profile of each sub-population of 
adventitial cells. Subsets of ALDH (low/high) adventitial cells were expanded 
in normal culture conditions for 3 to 4 passages to obtain enough cells to 
perform the experiments. Cells were detached with trypsin, counted and the 
ALDEFLUOR assay was performed following manufacturer instructions.  
 ALDH subsets of pericytes were not sorted due to the low number of ALDH 
high cells that were not able to expand in vitro. However, since adventitial cells 
have the most primitive phenotype, I focused on the characterisation of ALDH 





 ALDH activity in both subsets of adventitial cells was similar (Figure 17,C), in 
the same manner percentages of ALDH high cells in both sub populations were 
similar (Figure 17,C). Moreover, cultured ALDH low adventitial cells now 
include an ALDH high compartment, which further suggests that ALDH activity 
in cultured perivascular cells is not relevant to distinguish the ALDH subsets of 
adventitial cells. 
 
In conclusion, adventitial cells have higher ALDH activity than pericytes. 
However, the transition into MSCs after in vitro expansion makes both subsets 
similar in terms of ALDH activity. This may indicate that ALDH activity only 
serves as a marker of adventitial cells in uncultured cells, making the 
correlation between in vitro and in vivo studies difficult to establish. In addition, 
it is not clear whether ALDH low cells became high or if the opposite happened 












Figure 17 Quantification of ALDH activity in fresh and cultured perivascular cells 
A. Percentage of ALDH high cells within pericytes and adventitial cells. B Mean ALDH 
fluorescence intensity (MFI) of percytes and adventitial cells. C. After culture of ALDH high and 
low adventitial cells, differences in ALDH MFI disappear.D. After culture,ALDH high and low 
adventitial cells have similar percentages of ALDH high cells. Unpaired t-test with Welch’s 





4.3.2 ALDH activity is correlated with CD34 expression in 
adventitial cells, and association and interactions 
network analysis suggests functional roles in vessel 
remodelling  
 
The surface receptors that identify pericytes and adventitial cells have been 
previously described to be markers of stem cells in different organs. Since 
ALDH activity is well characterized as a stem cell marker, I decided to analyse 
the expression of perivascular cell markers in the different ALDH 
compartments. 
 
 In order to assess the relation of the two markers that distinguish pericytes 
(CD146) from adventitial cells (CD34), I measured the mean fluorescence 
intensity of CD34 and CD146 in the high and low ALDH compartments. It was 
found that higher ALDH activity is related with higher CD34 expression, 
whereas CD146 expression remains the same in both compartments (Figure 
18,A&B).  
To further investigate the relationship of CD34 with ALDH, network analysis 
using GeneMania.org was performed. GeneMania finds genes that are related 
to the set of input genes, using a large set of functional association. These 
data include protein and genetic interactions, co-expression, pathways, protein 





 I queried the two genes of interest (Figure 19) revealing interactions with 
genes involved in vessel remodelling such as PDGFRb, KDR, TIE1, among 
others.  I decided to use the ALDH1 family since it is the one described as 
present in the ALDH high compartment. However, whether a specific ALDH1 
isoform is the one metabolising the ALDEFLUOR reagent is yet to be 
confirmed.  
 
In conclusion, I here show that ALDH and CD34 expressions are correlated in 
processes involved in blood vessel growth and development. Among the 
genes in the network I found well known markers involved with perivascular 
cells such as: PDGFRb, COL15A1, KDR, TIE1 and ENG. This suggests that 
ALDH1A1 expression/activity is correlated with different processes such as: 
vasculogenesis, endothelial cell development, extracellular matrix 
organization, integrin binding and VEGF pathways among others. However, 
this requires further validation by immunohistochemistry for example that 





















Figure 18 Mean fluorescence intensity of perivascular cell markers reveals a relation 
with ALDH activity.  
The mean fluorescence intensites of CD146 in pericytes (A) and CD34 in adventitial cells (B) 
were measured in the low and high ALDH compartments showing that expression of CD34, 
but not CD146, is related with ALDH activity. Paired t-test was used for all data sets. Data are 











Figure 19 Protein interaction analysis of CD34 and ALDH1A1.  
Network analysis of CD34 and ALDH1A1 was performed using Genemania 
(https://genemania.org). This shows the different types of networks where CD34 and 
ALDH1A1 are involved. Several of the genes in the network are involved in endothelial cell 
proliferation, vasculogenesis, regulation of vasculogenesis and extracellular matrix 




4.3.3 The ALDH high compartment is dependent on cell 
density in culture 
Due to the fact that ALDH activity is similar in ALDH low and high adventitial 
cells once they are expanded in vitro (Figure 17), I decided to study the 
ALDEFLUOR assay again to document the changes of ALDH activity in 
culture. It is well known that confluence of cells affects proliferation in vitro. 
Therefore, I hypothesized that in culture ALDH activity is dependent on cell 
confluence.  
 
In order to assess how cell density affects results of the ALDEFLUOR assay, 
ALDH low adventitial cells were seeded at different densities. Only ALDH low 
cells were used since ALDH high cells were similar in previous analysis. Cells 
at a density of 5000 cells/cm2 showed a higher number of ALDH high cells 
compared to those seeded at a 10,000 cells/cm2 (Figure 20). This indicates 
that in culture, ALDH activity is only present in proliferative cells that maintain 

















Figure 20 The ALDEFLUOR assay is affected by confluence of cells. 
 ALDH low adventitial cells were seeded at 5000 and 10000 cells/cm2 and ALDEFLUOR 
assay was performed to assess the effect on the ALDH high compartment. Cells cultured at 




4.3.4 PDGFRα and -β do not show differential expression in 
perivascular cells  
Platelet derived growth factor receptors (PDGFRs) α and β are expressed in 
subsets of perivascular cells (Chen et al., 2015; Murray et al., 2017). The 
expression of these receptors has been linked to the production of collagen 
and fibrosis as well as new muscle cells (Jensen et al., 2018). Studies in our 
laboratory have previously shown that a subset of PDGFRβ+ perivascular cells 
co-expressing PDGFRα are highly adipo-fibrogenic (Jensen et al., 2018).  
 
Due to the high importance of PDGF receptors in fibrosis and regeneration, we 
analysed the expression of the receptors in pericytes and adventitial cells 
(Figure 21, A&B), and in the ALDH subsets of adventitial cells (Figure 21, 
C&D). Comparing adventitial cells and pericytes we found no differences in the 
percentage of cells expressing only PDGFRβ, or in double positive cells 
expressing PDGFRβ and α. Published and unpublished data from our 
laboratory have shown that adventitial cells are the main perivascular cell type 
expressing PDGFRα. It was hypothesised that ALDH high adventitial cells 
have a different percentage of double positive cells compared to ALDH low 
cells. However, we found no differences in either single positives for PDGFRβ 
or double positives expressing also PDGFRα (Figure 21, C&D). Interestingly, 






Figure 21 Analysis of PDGF receptors in perivascular cells derived from adipose tissue.  
Adipose tissue was processed to get a single cell suspension, stained with antibodies and run 
through a flow cytometer to analyse percentages of cells expressing PDGF receptors. A. 
Analysis of pericytes and adventitial cells expressing PDGFRβ, but not α. B. Perivascular cells 
expressing both PDGFRβ and PDGFRα. C.  Expression of single positives for PDGFRβ in 
ALDH subsets of adventitial cells. D. Expression of double positive cells in ALDH subsets of 








4.3.5 ALDH high adventitial cells, but not ALDH low 
adventitial cells, are clonogenic 
In order to assess the heterogeneity of adventitial cells, we performed single 
cell index sorting by FACS to expand clones further experiments.  
 
It was found that only ALDH high adventitial cells are clonogenic (n=3), 
whereas cells from the ALDH low compartment are not able to proliferate in 
clonal conditions. The clonal efficiency was between 10 to 20% of ALDH high 
adventitial cells, and it was donor dependent. From the clones that were 
expanded only 35% were able to differentiate into mesodermal cell lineages. 
 
Osteogenesis potential of the expanded clones was quantified by extracting 
alizarin red taken up by osteoblasts showing a small subset of clones with high 
osteogenic potential (Figure 22). This gives more evidence of the 



















Figure 22 Osteogenic potential of ALDH high adventitial cell clones. 
 Single cell index sorting was performed on adventitial cells with high ALDH activity. Derived 
clones were expanded then induced to differentiate into osteoblasts. Quantification was 
performed by extracting Alizarin red from osteoblasts and determining concentration using 




4.3.6 RNAseq reveals transcriptional differences between 
ALDH low and high adventitial cells before culture  
In order to corroborate the findings obtained from single cell qPCR analysis 
(Hardy et al., 2017), I performed RNAseq analysis on different populations of 
perivascular cells in both settings, freshly sorted and after they become MSC-
like cells in culture. Principal component analysis (PCA) shows the clustering 
of the different perivascular cell populations before and after culture  (Figure 
23). Cultured ALDH low and high adventitial cells cluster together, due to 
similarities between these cell types. On the other hand, cultured pericytes 
appear to be different compared to the other cultured perivascular cells. In 
addition, the freshly sorted whole population of adventitial cells and ALDH 
subsets were similar. As expected, pericytes are different from adventitial cells 
at the transcriptomic level and this is maintained in culture. 
 
We next looked at the genes that are upregulated or downregulated when 
comparing freshly sorted ALDH subsets of adventitial cells (Figure 24, A). We 
did not find a clear difference between ALDH low and high in non-cultured 
cells. Importantly, upon culture, ALDH subsets are similar (Figure 24,B). This 
corroborates what we have seen in the functional assays, that culture 
conditions make the cells similar.  
 
We found that pericytes have a different transcriptomic profile when compared 




are maintained in culture (Figure 25). This raises questions about the 
heterogeneity of common MSCs that are isolated by plastic adherence, where 
they may be clonal selection. Moreover, the stromal vascular fractions contain 
pericytes and adventitial cells and whether a specific type of perivascular cells 
proliferate faster and if there are functional differences.   
 
Finally, by analysing transcripts in ALDH subpopulations I found genes that 
were uniquely expressed by ALDH high adventitial cells. Although there were 
many genes expressed exclusively by the ALDH high subset, only the ones 
with the most transcripts were selected (Table 8). I used RPMK (reads per 
kilobase of exon per million mapped reads) which takes into account both 
library size and gene length in within‐sample comparisons. These genes may 
help us identify the function and find new markers to identify this ALDH high 
population in situ. Indeed, by querying the list of these genes uniquely 
expressed by ALDH high adventitial cells on The PANTHER (protein 
annotation through evolutionary relationship) classification system 
(http://www.pantherdb.org/), which analyses genes sets by gene function, 
ontology, and pathways, enrichment in different molecular pathways was 
found (Figure 26).  Among the pathways enriched, we found angiogenesis, T 
cell activation, apoptosis signalling, PDGF, ATP synthesis and endothelin, 
among others.  This suggests that ALDH high adventitial cells have specific 
functions after activation after injury or tissue turnover, being involved in 





Figure 23 Principal component analysis (PCA) shows correlation between different subsets of 
perivascular cells. 
 Sub-populations of perivascular cells were sorted according to their ALDH activity. RNA seq was 
performed in freshly sorted cells and cultured cells. Principal component analysis shows groups of cells 
clustering in different planes PCA was done using the sofware PARTEK. n=1 (3 human donors pooled 
together) 
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Figure 24 Volcano plots of ALDH subpopulations before and after culture. 
 Sub-populations of perivascular cells were sorted according to their ALDH activity. RNA was 
sequenced in freshly sorted cells and cultured cells.  Volcano plots show the genes up and 
down regulated in ALDH subsets of adventitial cells freshly sorted and after culture. A 
comparison of genes up/down regulated in freshly sorted ALDH low vs freshly sorted ALDH 
high adventitial cells. B comparison of genes up/down regulated in cultured ALDH low vs 




 Figure 25 Volcano plots of ALDH subpopulations compared to pericytes before and 
after culture. 
Sub-populations of perivascular cells were sorted according to their ALDH activity. RNA was 
sequenced in freshly sorted cells and cultured cells.  Volcano plots show the genes up and 
down regulated of ALDH subsets in freshly sorted adventitial cells and pericytes, before and 
after culture. A. Freshly sorted ALDH high adventitial cells vs freshly sorted pericytes. B. 
Freshly sorted ALDH low adventitial cells vs freshly sorted pericytes. C. Cultured ALDH high 











Table 8 Genes uniquely expressed by ALDH high adventitial cells with the higher 
number of transcripts 
Gene ALDH LOW ADV 
(RPMK) 
ALDH HIGH ADV 
(RPMK) 
GSN 1 38261 
FOS 1 38219 
COX1 1 27297 
COX3 1 26612 
ND4 1 21370 
ND4L 1 26449 
CYTB 1 24050 
COX2 1 14607 
ND2 1 12598 
ATP6 1 7868 








































































































































MSCs and their in vivo counterparts, perivascular cells  are involved in many 
processes such as angiogenesis, adipogenesis, osteogenesis, tissue repair, 
among others.  For that reason, we analysed the expression of genes involved 
in those different processes in freshly sorted cells and after they have been 
expanded in vitro. We created heatmaps that cluster genes according to their 
expression using the R package “Pheatmap”.  
 
In the cohort of genes expressed by freshly sorted cells (Figure 27), we saw a 
similar expression pattern in angiogenesis related-genes, although some 
genes differentially expressed in adventitial cells with high ALDH activity when 
compared to both, ALDH low adventitial cells and pericytes. We saw a similar 
trend in the other data sets analysed. Expression of tissue repair related genes 
was similar between ALDH subsets of adventitial cells, whereas in pericytes a 
group of genes clustered differently. In the case of adipogenesis, pericytes 
express a group of genes clustering differently than in ALDH subsets including 
ADIPOQ and leptin. Lastly, osteogenesis related genes in ALDH 
subpopulations are differentially expressed. We found COL1A1 only 
expressed in adventitial cells, and RUNX2 and BMP5 only expressed in the 
ALDH low adventitial cell population. 
 
We also analysed the same group of genes in culture expanded perivascular 
cells (Figure 28). We found similar results as in fresh cells. Most clusters of 




pattern is different from that in the freshly sorted cells, meaning that cultured 
cells may have a different effect in cell therapies. For angiogenesis, tissue 
repair, and osteogenesis, the expression pattern is similar. In adipogenesis, 
we observed that genes expressed in adventitial cells cluster differently, such 
as ADIPOQ, APOE, among others, whereas they are not expressed in 

















































































































































































































































































































































































































































































































































4.3.7 ALDH1A1 is the main ALDH isoform present in ALDH 
high adventitial cells, and it is lost upon culture  
 
ALDEFLUOR assay was developed to detect ALDH1 family members, 
however it has been reported that in different tissues several isoforms can 
metabolize the substrate used in the assay. 
 
In order to identify the main ALDH isoforms present in adventitial cells, we 
performed RNA sequencing on freshly sorted cells of the ALDH low and high 
compartments of adventitial cells. We found that ALDH1A1 is the isoform that 
appears to be more expressed in the ALDH high compartment (Figure 29, A). 
Although mRNA levels may not be correlated with enzymatic activity this 
observation gives us an indication as to which enzyme is metabolizing the 
ALDEFLUOR reagent. 
 
Since we observed that in culture the ALDEFLUOR activity was similar in 
ALDH low and high adventitial cells, we performed RNA sequencing on ALDH 
low and high adventitial cells  after 3 passages  of culture expansion. As 
expected, we found that  mRNA levels of these two subtypes are similar in 
culture conditions (Figure 29, B). Moreover, ALDH1A1 expression is 







Figure 29 ALDH isoform expression in freshly sorted and cultured adventitial cells. 
 A. RNA sequencing performed in ALDH low and high compartments of adventitial cells 
reveals the expression of different ALDH isoforms showing ALDH1A1 highly expressed in the 
ALDH high compartment. B. Subsets of adventitial cells were cultured and RNA sequencing 





4.3.8 ALDH1A1 is present in perivascular cells of different 
human organs including adipose tissue, heart  and 
uterus 
Taking into account the finding that ALDH1A1 is the main isoform present in 
the ALDH high cell compartment, we decided to assess ALDH1A1 expression 
in situ in different foetal and adult human tissues including white adipose 
tissue, heart, and uterus.  
 
Using different combinations of endothelial and perivascular cell markers, we 
were able to identify ALDH1A1 in the adventitial layer of adipose tissue in cells 
co-expressing CD34 (Figure 30). On the other hand, only few (almost none) 
pericytes expressed ALDH1A1 along with the pericyte marker α-SMA. These 
findings corroborate the data obtained by flow cytometry showing that 
adventitial cells have a higher percentage of ALDH high cells than pericytes. 
Next, human foetal heart was investigated to test whether ALDH1A1 
expression is similar in different tissues. We found that only a few cells in the 
adventitia layer express ALDH1A1, suggesting that this subpopulation of 
adventitial cells expressing CD34 and ALDH1A1 is rare (Figure 31). We could 
not find pericytes expressing ALDH1A1 in the foetal heart.   
 
Finally, adult human uterus in the proliferative stage shows  homogenous 
ALDH1A1 co-expression with CD34 through the adventitial layer (Figure 32). 
These results suggest that ALDH1A1 expression in the adventitial layer of 




this, analysis of tissues at different stages of remodelling or after injury is 
required. ALDH1A1 analysis was also performed in human foetal skeletal 
muscle,  adult brain, and foetal limb. Data show that  ALDH1A1 is primarily 








Figure 30 ALDH1A1 expression in the perivascular cells of human adipose tissue. 
ALDH1A1 antibody was used along with CD34 and a-SMA marking adventitial cells and 
pericytes, respectively. Ulex europaeus lectin was also used to mark the endothelium along 
with CD34. It was found that adventitial cells expressing CD34 also express ALDH1A1 and 
that some pericytes co-express ALDH1A1 with a-SMA. Arrows mark CD34+ ALDH1A1+ cells  

















Figure 31 ALDH1A1 expression in the adventitial layer of blood vessels in the foetal 
heart. 
A combination of perivascular and endothelial cell markers was used along ALDH1A1 to 
detect cells expressing ALDH1A1 in the adventitial layer. Cells expressing CD34 and 
ALDH1A1 (arrows) as well as ALDH1A1 negative (arrow heads) were found in various 
vessels throughout the tissue showing that the adventitial cells expressing CD34 include a 









Figure 32 ALDH1A1 expression in the adventitial layer of adult uterus. 
A combination of perivascular and endothelial cell markers was used along with ALDH1A1 
antibody to detect perivascular cells expressing ALDH1A1. Cells expressing CD34 and ALDH1A1 
were found in various vessels throughout the tissue showing that the adventitial cells expressing 
CD34 harbour a sub-population of cells expressing ALDH1A1 (arrows), a marker of stem cells, 




4.4 DISCUSSION  
The work in this chapter sought to study a novel subset of perivascular cells 
with high ALDH activity, specifically, adventitial cells in large vessels, which 
showed higher ALDH activity than pericytes. In a series of different analyses 
including flow cytometry, in vitro assays, immunohistochemistry, and RNA 
sequencing, I characterized ALDH high cells in their in vivo niche and in vitro. 
I also identified ALDH1A1as a novel marker for adventitial cells that mark a 
subset of progenitor cells.  
 
4.4.1 Characterisation of ALDH activity in pericytes and 
adventitial cells, and how culture modifies ALDH 
activity 
First, it was corroborated that adventitial cells comprise the majority of the 
stromal vascular fraction, which may have implications when using adipose 
tissue-derived progenitors for cell therapy. Second, it was demonstrated that 
both types of perivascular cells can be isolated according to their ALDH 
activity, confirming previous research demonstrating ALDH activity being 
higher in adventitial cells (Hardy et al., 2017). However, now we were able to 
quantify this by calculating the mean fluorescence intensity in the 
ALDEFLUOR assay. Moreover, I further analysed the ALDH high compartment 
of perivascular cells finding that pericytes and adventitial cells have the same 
percentage of ALDH high cells, but the activity is significantly higher in 
adventitial cells. We demonstrated that once perivascular cells are expanded 




similar in terms of percentage of ALDH high cells and ALDH activity, quantified 
by mean fluorescence intensity, and mRNA levels in cultured cells. To our 
knowledge, this has not been previously reported. ALDH has been used to 
characterize stem cells from different types of cancer (Tomita et al., 2016; Mele 
et al., 2018; Zhou et al., 2019). However, modifications caused by in vitro 
expansion need to be considered. Especially, cell density during expansion 
changes the percentage of cells in the ALDH high compartment. 
 
I sought to analyse the relationship between the intensity of expression (flow 
cytometry) of the perivascular cell markers CD146 and CD34, and ALDH 
activity. Indeed, it was found that higher expression of the membrane receptor 
that distinguishes adventitial cells from pericytes, CD34, is correlated with 
higher ALDH activity. The stronger the signal of the cell marker in flow 
cytometry, the more ALDH activity. This finding led to the analysis of protein 
interaction between CD34 and ALDH1A1. Since CD146 expression levels did 
not correlate with ALDH activity and the project is focused on the most primitive 
cell type (adventitial cells), we did not analyse protein interaction of CD146 and 
ALDH. This ALDH1A1 isoform was chosen due to the fact that ALDEFLUOR 
assays were created to detect this specific isoform (Jones et al., 1995; Storms 
et al., 1999). Therefore, transcriptome analysis is needed to corroborate the 
ALDH1A1 specificity since different isoforms have been shown to metabolize 
the ALDEFLUOR reagent and it varies between cell types and tissues (Zhou 
et al., 2019).  Indeed, ALDH1A1 presence in the ALDH high compartment was 




 Interestingly, the interaction network of proteins showed molecules involved 
in vasculogenesis and extracellular matrix reorganization, which are known to 
play a role in vessel remodelling, suggesting that ALDH1A1 expression  is 
needed when these processes are carried out by cells in the adventitia 
expressing CD34. Indeed, different subsets of adventitial cells have been 
involved in myofibroblast differentiation (Siow et al., 2003; Kramann et al., 
2015)  as well as adipogenic and osteogenic differentiation (Ding et al., 2019). 
It has been suggested that VEGFR2+ adventitial cells give rise to 
cardiomyocytes (Mekala et al., 2018). In conclusion, these data suggest along 
with different previous reports that ALDH1A1 marks a rare subset of primitive 
perivascular cells, especially adventitial cells. In order to characterise and 




The ALDEFLUOR assay has been used to isolate MSCs with high ALDH 
activity (Sherman et al., 2017; Najar et al., 2018). However, these cells have 
been expanded and the original identity of the cells that gave origin to these 
MSCs is not known. Here, a more prospective approach was used. We sorted 
MSC progenitors from the in situ niche according to  ALDH activity, then cells 
were cultured. After expansion, the ALDEFLUOR assay was performed again 
and no difference between the subsets was found in terms of activity or 
percentage of ALDH high cells. Moreover, mRNA levels of ALDH isoform was 




ALDH high compartment of cells is dependent on cell confluence. Previous 
studies showed that YAP/TAZ is involved in cell proliferation, and reacts by 
mechanical contact between the cells (Seo, 2018). This raises the question as 
to whether the ALDH high cells isolated from in vitro cultures may actually  
proliferate due to  sensing mechanical cues (Kurpinski et al., 2006) and not  to 
ALDH activity. Cultured MSCs from the ALDH high compartment sorted and 
expanded again in vitro showed the same profile when the ALDEFLUOR assay 
was performed once more (not shown). This led me to speculate that ALDH 
activity in vitro marks proliferating cells but not a specific progenitor cell, and 
the use of the ALDEFLUOR assay in vitro may need to be better characterized. 
Other groups showed that freshly sorted ALDH high bone marrow cells are 
better at establishing blood flow after hind limb ischemia (Capoccia et al., 
2009), suggesting that freshly sorted cells may be more beneficial for cell 
therapy. However, high cell numbers are required for injection into patients. 
Hence, in vitro expansion may be unavoidable in most instances.  
 
Next, ALDH low and high compartments of adventitial cells were analysed for  
expression of PDGF receptors. Cells expressing combinations of these 
receptors have been described to give rise to myofibroblasts but also muscle 
cells (Murray et al., 2017; Jensen et al., 2018). PDGFRβ+ perivascular cells 
expressing PDGFRα are highly fibroadipogenic, whereas single positive 
PDGFRβ+ cells are pro-myogenic (Jensen et al., 2018). Indeed, PDGFRα has 
been shown to be highly involved in fibrosis (Hayes et al., 2014; Uezumi et al., 




the ALDH compartments of adventitial cells expressing either only PDGFRβ, 
or both receptors, PDGFRβ and α. The results showed no differences in the 
percentage of cells in either subset, indicating that ALDH activity may not be 
correlated with PDGF receptor expression. However, we cannot rule out that 
under pathological conditions the expression of these receptors changes. 
Indeed, published (Murray et al. 2017) and preliminary data from our laboratory 
showed that after heart injury, PDGFRα expression is upregulated in 
perivascular cells and contribute to organ fibrosis.  
 
Finally, ALDH subsets of adventitial cells were characterised in vitro to analyse 
heterogeneity between clones. It has been reported that MSCs are clonogenic 
and suggested that only some clones in the whole population are real MSCs, 
able to differentiate into mesodermal cell lineages (Chamberlain et al., 2007; 
Lv et al., 2014). We found that ALDH low adventitial cell clones do not expand 
after sorting, whereas ALDH high adventitial cell clones reach confluency in 7 
days. ALDH low cells were only able to adhere and proliferate when sorted 
cells were plated at high numbers. Although they proliferate slowly in the 
beginning, after 2-3 passages they proliferate almost at the same rate as ALDH 
high cells. This may be due to the harsh conditions of the cell sorting, that 
clones with low ALDH activity are less resistant to sorting. On the other hand, 
ALDH high adventitial cell clones were able to expand after sorting. Once 
under differentiation conditions, only a few clones were able to differentiate 
into the osteogenic lineage, providing more evidence that only a few clones 




cells have been shown to be heterogeneous, as previously reported by our 
laboratory using single cell qPCR data (Hardy et al., 2017) (Figure 33). 
 
To summarise this section, ALDH activity marks a primitive population of 
perivascular cells. This ALDH high compartment does not differentially express 
PDGF receptors, involved in fibrosis, compared to the ALDH low compartment. 
During in vitro expansion this characteristic ALDH activity, that identified two 
subsets of adventitial cells, is lost. Moreover, in culture conditions ALDH 
activity  is dependent on cell density. Lastly, only ALDH high adventitial cells 

























Figure 33 Principal component analysis of single perivascular cells from ALDH 
subsets. 
Analysis of gene expression by single cells in populations of ALDH subsets of adventitial 
cells and pericytes showed heterogeneity of the different clones. Circles: ADV; triangles: 





4.4.2 Transcriptomic analysis of ALDH subsets of adventitial 
cells and pericytes reveals differences between MSC 
progenitors. 
Transcriptomic analysis allows for the comprehensive study of genes 
expressed in a specific cell population that may help reveal functional traits. 
Network analysis of  500 genes on single cells was performed by members of 
our laboratory  showing that perivascular cells have a hierarchy according to 
ALDH activity, adventitial cells with high ALDH activity being the subset with 
the most primitive phenotype. However, a comprehensive analysis of the 
transcriptome of these ALDH subsets of perivascular cells has not been 
performed. Here, I showed that there are transcriptional major differences 
between pericytes and adventitial cells. Moreover, ALDH high adventitial cells 
exhibit a different transcriptome compared to the ALDH low counterpart before 
culture expansion.  
 
Principal component analysis (PCA) is a method to simplify complex high 
dimensional data. PCA is similar to clustering in the sense that it is an 
unsupervised learning method that finds patterns with no background 
knowledge about the samples analysed (Lever et al. 2017). PCA analysis of 
our different populations of cells showed that adventitial cells (whole 
population) and derived ALDH subsets cluster together, although there are 
slight differences between them. As expected, pericytes, either freshly sorted 
or cultured, are transcriptionally different compared to adventitial cells. Next, 




ALDH subsets of adventitial cells were compared. Differences between ALDH 
subsets were minimal. Nevertheless, when pericytes and either ALDH subset 
of adventitial cells were compared, a clear difference in up/down regulated 
genes was observed. Pericytes and adventitial cells come from different 
locations in the human body and have different functions, so it was not 
unexpected that they will have different transcriptomes. Interestingly, this 
opens up the question of what approach is better to expand MSCs in culture. 
As it can be seen from my results, pericytes have an entirely different identity 
compared to adventitial cells after in vitro expansion.  
 
In order to elucidate the functions of ALDH high cells in vivo, I found genes 
uniquely expressed by ALDH high adventitial cells and with the highest number 
of reads. As expected, many of these genes are involved in metabolism. The 
list of genes was queried in an ontology database (PANTHER) to find 
pathways related to the expression of this gene set. Angiogenesis, PDGF 
signalling, activation of immune cells, endothelin pathways, among others, are 
active in this ALDH high adventitial cell subset. Cells in the adventitia have 
been described to be involved in vascular remodelling, interact with immune 
cells, and differentiate into other cell types (Siow et al., 2003; Moos et al., 2005; 
Campbell et al., 2012; Kramann et al., 2016; Ding et al., 2019; Wang et al., 
2019). This analysis suggested that cells with high ALDH activity in the 





Finally, four pathways involved in MSC differentiation potential (osteogenesis 
and adipogenesis) and therapeutic benefit related to MSCs (angiogenesis and 
tissue repair) were analysed in the ALDH subsets of adventitial cells and  
pericytes. Heatmaps were created by clustering the expression levels of the 
genes in every cell type in cultured or uncultured conditions. There were no 
clear differences in either of the pathways, although some clusters of genes 
were differentially expressed.  
 
In other lineages there were some differences in gene expression. For 
example in osteogenesis, only subsets of adventitial cells expressed COL1A1 
and, interestingly, only ALDH low adventitial cells expressed RUNX2 and 
BMP3. Lastly, in the adipogenesis related gene group, the expression profile 
was similar between all cell types. However, only pericytes expressed LEP and 
ADIPOQ, key genes involved in adipogenesis. A recent study has shown that 
human MSCs contain sub-populations of adipocyte progenitors (Min et al., 
2019). By isolating clones from adipose tissue, they found cell types with 
different adipogenic differentiation capacities. Interestingly, one of the genes 
correlated with adipogenesis  was MCAM (CD146), a pericyte marker, which 
is consistent with our transcriptomic analysis suggesting that pericytes are 






On the other hand, once in culture, most genes drastically changed expression 
becoming more similar between the groups. LEP expression is downregulated 
in pericytes and ALDH high adventitial cells and only ALDH low adventitial cells 
express ADIPOQ. This highlights the complexity of studying perivascular cells 
and the dramatic changes in gene expression happening in culture. Once 
perivascular cells become MSCs it is difficult to tell whether they will behave 
as they would in their in vivo niche.  
 
In summary, transcriptomic analysis shows that ALDH subsets of adventitial 
cells are different in freshly sorted conditions, but once they are expanded in 
vitro they become phenotypically similar. On the other hand, I also show that 
pericytes after in vitro expansion are transcriptionally different than adventitial 
cells. Lastly, it is worth noting that after in vitro expansion native pericytes and 
adventitial cells dramatically modified their transcriptome compared to their in 









4.4.3 ALDH1A1 as a novel marker for perivascular progenitor 
cells  
The ALDEFLUOR assay was developed to analyse the activity of ALDH1A1. 
However, different isoforms of ALDH can metabolize the ALDEFLUOR 
substrate in different cell types (Zhou et al., 2019). Indeed, my data showed 
that ALDH1A1 was the isoform with the highest number of transcripts in the 
ALDH high compartment, compared to the other isoforms. This led me to use 
an anti-ALDH1A1 antibody to detect this isoform in the native niche. ALDH1A1 
was expressed primarily in the adventitial layer of large vessels in the human 
foetal heart, adipose tissue, skeletal muscle, and uterus. Interestingly, 
ALDH1A1 gene expression was absent once adventitial cells were placed in 
culture. Moreover, the other isoforms were equally expressed in both subsets 
of adventitial cells, corroborating what we saw in previous sections of this 
thesis, in which ALDH activity in cultured cell subsets of adventitial cells was 
not relevant due to their phenotypic similarities acquired upon culture 
expansion.  
 
ALDH1A1 has been described as a stem cell marker in different tissues 
(Tomita et al., 2016). It is mainly involved in  retinoic acid mediated cell 
proliferation and differentiation (Vassalli, 2019). It has already been proposed 
that adventitial cells have a more primitive phenotype than pericytes (Hardy et 
al., 2017), and that pericytes may not act as MSCs in vivo (Guimarães-
Camboa et al., 2017). These findings suggested that the adventitia is a source 




subset of perivascular cells. In the foetal heart, only a few cells express 
ALDH1A1 in the adventitia. On the other hand, pericytes expressing ALDH1A1 
were absent in the foetal heart and very rare in  other tissues. In adipose tissue, 
only one pericyte was expressing ALDH1A1 along with α-SMA (Figure 30).  
 
Since ALDH1A1 is a stem cell marker, do ALDH1A1+ adventitial cells act as 
progenitor  cells after injury or in disease?. As seen in the network analysis 
using ALDH1A1 and CD34, many genes involved in vascular remodelling and 
extracellular matrix organization interact with our two genes of interest. 
Furthermore, genes exclusively expressed in ALDH high adventitial cells 
showed that important factors such as PDGF, known to be involved in cell 
proliferation,  angiogenesis, and the activation of immune cells were 
particularly associated with the ALDH high population in situ.  
 
In conclusion, ALDH1A1 is a novel marker of adventitial progenitor cells and 
of some pericytes, and is consistently found in human organs. This new marker 
may identify a population of progenitors involved in tissue repair after injury or 
disease. However, the only way to document this is to use an animal model 
where we can track ALDH1A1+ cells in the adventitia after injury. Lastly, it 
would be interesting to investigate what subsets of perivascular cells are 


















Chapter 5 PRELIMINARY ANALYSIS OF 
ALDH1A1 EXPRESSING 
PERIVASCULAR CELLS IN 











5.1 Introduction  
Perivascular cells are also involved in different pathological conditions. For 
example, cancer requires the formation of new vessels to grow and eventually 
spread to other parts of the body (Nishida et al., 2006). Pericytes have been 
studied in this regard (Paiva et al., 2018), but the complex interplay of different 
factors and the heterogeneity of perivascular cells make the research difficult.  
 
ALDH1 expression in cancer has been described (Tomita et al., 2016). It has 
been suggested that high ALDH activity in tumour endothelial cells marks a 
population of cells that  drive angiogenesis during tumour growth (Ohmura-
Kakutani et al., 2014). Moreover, ALDH has also been used along with CD44 
and other stem cell markers to isolate cancer stem cells (Li et al., 2017). It is 
well documented that ALDH activity confers drug resistance as well as radio 
resistance (Januchowski et al. 2013). Recently, it has been shown that 
glioblastoma hijacks pericytes to promote tumour growth (Valdor et al., 2019). 
However, whether  a specific subset of pericytes or adventitial cells is involved 
in tumour growth  has not been described.  
 
On the other hand, perivascular cells, pericytes and adventitial cells, have 
been shown to be involved in different pathologies including atherosclerosis, 




Shaw et al., 2018). However, a study of specific subpopulations is needed to 
further categorise and classify which subtypes may be of therapeutic interest.  
 
Expression of ALDH1A1 in perivascular cells, and specifically in pathologies 
such as cancer and fibrosis, to our knowledge, has not been thoroughly 
studied. In this chapter, I performed a preliminary characterisation of 
ALDH1A1+ perivascular cells in human cancer and fibrosis after rotator cuff 

















5.2 Hypothesis and aims  
 
5.2.1 Hypothesis  
 
“ALDH1A1 marks a population of perivascular cells involved in 
pathological conditions such as cancer and fibrosis” 
 
In the previous section a novel marker for perivascular cells and specifically of 
adventitial cells was found. ALDH1A1, a stem cell marker, is expressed in 
perivascular cells of different organs. This may indicate that ALDH1A1 marks 
a population of ubiquitous perivascular progenitors. 
 
5.2.2 Aims  
• To characterise ALDH1A1 expression in human brain cancer 
(glioblastoma multiforme) 
 
• To test if ALDH1A1 expression is also found in mouse perivascular 
cells  
 
• To analyse the expression of ALDH1A1 in skeletal muscle postinjury 





5.3 Results  
5.4 ALDH in perivascular cells in glioblastoma 
multiforme (GBM) 
In order to characterize ALDH1 in glioblastoma multiforme, the tissue was 
digested with collagenases. The ALDEFLUOR assay was performed on single 
cell suspensions, antibodies then added and finally samples were analysed by 
flow cytometry. We used CD56, an antigen that marks neural cells, to discard 
cells of neural lineage.  
A small population of CD146+ pericytes was found in the ALDH high 
compartment and comprises 13.35% ± 1.35% of all pericytes in the tissue 
(Figure 34). In this experiment we could not find a clear population of CD34+ 
adventitial cells, and this was consistent between two donors. 
Next, we investigated ALDH1A1 in situ as we did in other human tissues. We 
performed staining with UEA-1 to mark the endothelium and anti-ALDH1A1 
antibody. Cells expressing ALDH1A1 in close contact with the endothelium 
were found in different areas of the tumour. The expression of ALDH1A1 in 
pericytes was present in only a small subset (Figure 35). Adventitial cells 
expressing CD34 and ALDH1A1 were found as well (Figure 35). However, this 
cell type was rare and only found in abnormal vessels with an aberrant 
adventitia layer, smaller in size compared to arteries and veins. This may be 
due to the modification caused in the tissue by abnormal growth of tissue 








Figure 34 ALDH activity of pericytes from glioblastoma. 
A. Tumour brain tissue with glioblastoma multiforme was digested and analysed with the 
ALDEFLUOR assay and perivascular cell markers. A population of pericytes expressing 





Figure 35 ALDH1A1 expression in perivascular cells in glioblastoma. 
ALDH1A1 antibody was used along with perivascular and endothelial cell markers to 
assess the expression of this ALDH isoform in pericytes and adventitial cells in 
glioblastoma multiforme. Pericytes expressing ALDH1A1 were found in small vessels 
through the tissue. Adventitial cells expressing CD34 also express ALDH1A1, however this 
population was rare. Arrows mark ALDH1A1+ perivascular cells, whereas arrowheads 





5.5 ALDH1A1 characterization in mouse tissues 
after injury  
 
5.5.1 ALDH1A1 validation in mouse tissues 
Once we characterized the expression of ALDH1A1 in normal human tissues, 
we decided to investigate the role of this new marker after injury. First, we 
optimized the protocol for antibody staining on mouse tissues (Figure 36). A 
combination of α-SMA, to mark pericytes and smooth muscle cells, and 
ALDH1A1 was used in the mouse heart. ALDH1A1 expression was specific of 
the adventitial layer of the aorta (Figure 36, A), and found in some large 
vessels in the heart muscle and muscle cells (Figure 36, B&C).  
This experiment confirmed the expression of ALDH1A1 in adventitial cells. The 
aorta shows high expression of ALDH1A1 whereas in other layers it is almost 
absent. Pericytes expressing ALDH1A1 were not found. This is consistent with 
what it was seen in the human foetal heart which showed that ALDH1A1 

















Figure 36 ALDH1A1 expression in the mouse heart. 
The ALDH1A1 antibody was used in combination with anti α-SMA to identify pericytes and 
adventitial cells. α-SMA expression (green) marks the media layer of large vessels. Arrows 
show cells expressing ALDH1A1 (magenta) in the adventitia of large vessels and arrowheads 
point to cells expressing ALDH1A1 that are unrelated to blood vessels. Scale bar represents 




5.5.2 ALDH1A1 expression increases in muscle cells in 
chronic muscle injury of the rotator cuff  
It is known that perivascular cells contribute to fibrotic tissue in skeletal muscle 
(Kramann et al., 2015; Murray et al., 2017). Previously, members of our 
laboratory found that PDGFRβ+ cells contribute to fibrosis in mouse chronic 
rotator cuff injury (Jensen et al., 2018). Therefore, using the same rotator cuff 
injury, we analysed how ALDH1A1 expression changes at different time points. 
 
In uninjured tissue, ALDH1A1 was detected in the adventitial layer localised 
adjacent to α-SMA expression marking the media layer (Figure 37). Five days 
after injury, proliferation could be noticed in the muscle fibres in areas proximal 
to blood vessels with some cells expressing ALDH1A1 in blood vessels. Some 
muscle cells overexpress ALDH1A1 which was more obvious by 2 and 6 
weeks post injury. ALDH1A1 expression in the perivascular area is absent 
after 2 weeks. By 6 weeks post injury, blood vessels appear to  lack  the 
adventitia layer. 
 
In the site of proliferation of muscle cells, we found an upregulation of 
ALDH1A1 in myocytes and muscle fibres (Figure 38). Clearly, fibres with three 
to five nuclei inside are ALDH1A1 high. These fibres with nuclei in the centre 
are known to be regenerating fibres. Overall, after injury ALDH1A1 is 
upregulated in immature muscle fibres. There are also different levels of 




ALDH1A1 high compared to other ones, this could mean that new immature 
myofibers express high levels of ALDH1A1 and once they mature the 
expression goes back to low/basal levels. Even though, we could not find 
conclusive evidence that perivascular cells contribute to muscle cells, it does 





















Figure 37 ALDH1A1 expression in chronic skeletal muscle injury. 
Uninjured and injured rotator cuff muscles were stained with antibodies against ALDH1A1 
(magenta) and α-SMA (green) at different time points (5 days, 2 weeks, and 6 weeks). 
ALDH1A1 expression increases after injury and is present in muscle fibres and some 
perivascular cells. After 2 weeks, ALDH1A1 expression in blood vessels is absent while some 






Figure 38 ALDH1A1 expression after 5 days of chronic rotator cuff injury. 
Rotator cuff muscle tissue after 5 days of injury was stained with  anti-ALDH1A1 antibody (purple) and 
α-SMA (green). Areas showing signs of cell proliferation upregulated  ALDH1A1 in immature muscle 
fibres. Mature muscle fibres (nuclei on the side) have basal levels of ALDH1A1 whereas in cells that 
seem to be proliferating the expression in higher. Arrows mark fiber with high ALDH1A1 expression 




5.6 Discussion  
In the previous chapter we showed that ALDH1A1 marks a novel population of 
perivascular cells. Now, I sought to obtain preliminary data on the expression 
of ALDH1A1 in pathological conditions (cancer and fibrosis). ALDH1A1 
expression, as previously mentioned, has been described to mark cancer stem 
cells and endothelial cells with more angiogenic potential. However, the 
expression of ALDH1A1 in perivascular cells, pericytes and adventitial cells, 
has not been characterized in cancer. On the other hand, other subsets of 
perivascular cells contribute to fibrosis; however, whether these subsets also 
express ALDH1A1 is not known. 
 
5.6.1 Glioblastoma multiforme contains a population with 
high ALDH activity, and the isoform ALDH1A1 can be 
found in pericytes  
In 2017 cancer was the second cause of mortality worldwide (Hassanpour and 
Dehghani, 2017). One of the most lethal tumours is glioblastoma (GBM) which 
is the most common of central nervous system tumours, with a 5-year survival 
rate of 5% (Delgado-López and Corrales-García, 2016). One of the main 
components of the tumour environment is the vasculature which is involved in 
tumour growth and metastasis (Schaaf, Garg and Agostinis, 2018). While 
pericytes have been described to be important for tumour growth, little is 





In this study, I investigated ALDH activity in perivascular cells in fresh brain 
tissue with GBM and also the expression of ALDH1A1 in situ on tissue 
sections. It was found that there is a population of pericytes expressing CD146 
with high ALDH activity which is consistent in at least 2 available donors. 
Endothelial cells with high ALDH activity exhibit a higher angiogenic potential 
in vitro and higher expression  of angiogenesis related genes such as VEGF-
A and VEGFR2 (Ohmura-Kakutani et al., 2014). Moreover, these endothelial 
cells show drug resistance (Hida et al., 2017). Here, it was found that pericytes 
also include a population with high ALDH activity. Based on previous studies 
on endothelial cells, I speculate that these cells are also involved in 
angiogenesis and tumour progression. Furthermore, in situ, only a small 
subset of pericytes express the ALDH1A1 isoform. Could this mean that this 
sub-population of pericytes expressing ALDH1A1 are the main driver of 
angiogenesis and tumour growth?  
 
Pericytes are particularly important for tumour growth. Indeed, glioblastoma 
stem cells can generate pericytes to support vessels which in turn promote 
tumour growth (Cheng et al., 2013), and also immunosuppression (Sena et al., 
2018). Thus, targeting of pericytes from glioblastoma is a feasible strategy to 
improve chemotherapy (Zhou et al., 2017; Guerra et al., 2018). More recently 
it was found that glioblastoma modulates pericytes to assist its progression 






It is worth mentioning that large vessels were not found in the sections of 
glioblastoma multiforme, only venules and arterioles in rare occasions. 
However, these vessels were abnormal and smaller in size compared to the 
usual large vessels found in other tissues.  
 
In conclusion, this novel population of pericytes expressing ALDH1A1 may be 
involved in tumour progression and targeting of this specific population may 
have therapeutic relevance. Indeed, ALDH1A1 has been described to promote 













5.6.2 ALDH1A1 is expressed in adventitial cells of the mouse 
aorta and interstitial cardiac muscle cells 
 
Next, the expression profile of ALDH1A1 was studied in the mouse. It was 
found that in normal uninjured heart and skeletal muscle, ALDH1A1 is 
expressed in perivascular regions of medium to large size vessels. In 
particular, the adventitial layer of the aorta was highly specific for ALDH1A1 
expression. This is consistent with what was found in the transcriptomic and in 
situ analysis of ALDH1A1, which strongly suggests that ALDH1A1 is a marker 
of the adventitial layer.  
 
The origin of myofibroblasts after injury is not yet clear. Several studies have 
implicated fibro-adipogenic progenitors and perivascular cells (Moyer and 
Wagner, 2011; Birbrair et al., 2013, 2014; Kramann et al., 2015; Murray et al., 
2017). Different subsets of perivascular cells have been shown to contribute 
to fibrosis. Nonetheless, other  populations of perivascular cells that also give 
rise to muscle cells which regenerate the tissue has also been reported. 
PDGFRβ+ subsets of cells give rise to fibrotic tissue as well as to muscle fibres. 
Another type of perivascular subset that is involved in fibrosis is gli1+ cells. 
Kramann et al. have shown that gli1+ cells are involved in fibrosis in different 
organs and calcification during kidney injury. Furthermore, ablation of these 
cells prevents fibrosis and calcification (Kramann et al., 2015, 2016; Schneider 




the maintenance of hematopoietic stem cells (HSC) (Corselli et al., 2013; Gao 
et al., 2018). 
 
Considering the results found in human in the previous chapter suggesting that 
native ALDH high cells are involved angiogenesis, proliferation and activation 
of immune system. Along with the fact that of stem cell marker ALDH1A1 is 
almost uniquely expressed in the tunica adventitia. I speculate that this subset 
of adventitial cells expressing ALDH1A1 act as progenitor and regulate 
immune responses.  
 
5.6.3 ALDH1A1 is upregulated in skeletal muscle fibers  
Lastly, chronic injury of the rotator cuff was analysed to assess the expression 
profile of ALDH1A1+ cells after injury. This same model was previously used 
by our collaborators at UCLA (Jensen et al., 2018).  
 
Here, it was found that ALDH1A1 is expressed by perivascular cells in different 
areas of the muscle. Interestingly, muscle fibres express ALDH1A1 at basal 
levels/low expression during homeostasis. Accumulation of cells, resembling 
proliferation, is seen at 5 days post injury along with upregulation of ALDH1A1 
in muscle fibres suggesting a role of this enzyme in regeneration. By week 2 
after injury, the tissue looks more normal with some muscle fibres negative for 




similar to the ones in the uninjured tissue are present. However, blood vessels 
lack an adventitia layer.  
 
Next, I focused on an area with high proliferation at day 5 after injury. Muscle 
fibres and many cells upregulated ALDH1A1 expression. These cells may be 
immune cells, PDGFRβ+ progenitors, satellite cells, and other cells. The most 
interesting feature of ALDH1A1 expression in muscle fibres is that only cells 
part of immature/regenerating fibres upregulated ALDH1A1. Once muscle 
fibres are mature ALDH1A1 expression returns to basal level. Indeed, 
ALDH1A1 has been involved in the proliferation (Condello et al., 2015). 
However, the majority of the research done on ALDH activity and the different 
isoforms was performed on cancer. Thus, it is difficult to link their findings to 
our data obtained from perivascular cells in normal tissues or in injury 
conditions.  
 
Taking into account ALDH1A1 involvement in retinoic acid metabolism which 
affects proliferation and differentiation of progenitor cells (Tomita et al, 2016), 
it can be suggested that upregulation of ALDH1A1 in these cells is required for 
progenitors to proliferate. ALDH1A1 is regulated by YAP of the hippo pathway 
(Song et al., 2018). The hippo pathway, particularly YAP, is involved in 
proliferation and differentiation of cells (Yu et al., 2013; Varelas, 2014). On 
another hand, YAP expression in MSCs has been described in pro-osteogenic 




(Pan et al., 2018). In HSCs, inhibition of ALDH stops the differentiation and 
increases the numbers of cells, and confers radioprotection (Muramoto et al., 
2010). On the other hand, it has been reported that ALDH1A1 expression in 
HSCs does not affect stem cell function and that it is not a critical regulator of 
stem cells (Levi et al., 2009). Therefore, ALDH1A1 likely has functional roles 
involved in differentiation and proliferation perivascular cells. 
 
Overall, our preliminary data support the hypothesis that ALDH1A1 expression 
after injury marks proliferative cells that are differentiating. In order to further 
corroborate our data more analysis is needed. For example an animal model 
where ALDH1A1+ cells are labelled with green fluorescent protein (GFP).  
Moreover, ALDH1A1 function in stem cells is more complicated than 
previously thought. In some studies with ALDH1A1-/- mice HSCs were normal 
and stem cell function was maintained (Levi et al., 2009), whereas in other 



















Chapter 6 CONCLUSIONS AND 














6.1 Conclusions  
Perivascular cells are a highly heterogeneous population of cells. Both 
pericytes and adventitial cells are located in different types of vessels. 
However, both cell types are considered an in-situ counterpart of 
mesenchymal stem cells (MSCs) (Crisan et al., 2008; Corselli et al., 2010, 
2012). In this thesis, we investigated different aspects of perivascular cells, 
and tried to link the native cell type to the in vitro counterpart. Adventitial cells 
with high ALDH activity were the main subject of the study due to having the 
most primitive phenotype. However, pericytes were also included in the 
transcriptomic analysis, especially in the in vitro conditions in order to assess 
the identity of both types of perivascular cell once they become MSCs. 
 
First, it was shown that ALDH activity marks a population of progenitors in vivo 
and importantly, culture conditions make ALDH activity dependent on cell 
density. Moreover, it was shown that expression levels of ALDH isoforms are 
similar in both ALDH subsets of adventitial cells once they are expanded in 
culture, confirming our results with the ALDEFLUOR assay. Overall, the use 
of ALDH activity as a marker of stem cells needs to be carefully assessed when 
using cells in vitro. 
 
Second, in vitro assays of ALDH subsets showed that they become similar 
after series of passages during expansion showing no significant difference 




needs to be considered. In the last year, human adipose tissue became scarce 
due to hospital regulations. More donors will be needed to consider the real 
distribution of the population, and the donor variability. Another explanation is 
the clonal section in vitro. Indeed, Selich et al. showed that clonal selection 
takes place at early passages and that only a few clones gave rise to the whole 
population of cells (Selich et al., 2016). Moreover, the phenotype change from 
perivascular cell to MSCs  erases the perivascular identity of these cells at 
least in regards to adventitial cells.  
 
Third, MSCs are the most used stem cells in clinical trials. However, there is a 
lack of understanding of the basic biology of these cells and where they come 
from. The majority of the research done on MSCs focuses on cells expanded 
in vitro without taking into account the origin of these cells and how this may 
affect therapeutic efficacy. Here, RNA sequencing analysis showed that 
freshly sorted pericytes and adventitial cells have different transcriptomes. 
Importantly, once they become MSCs after expansion in vitro, transcriptomic 
differences are maintained between pericytes and adventitial cells. This is 
especially important for therapeutics since MSCs from different types of 
perivascular cells have different gene expression profiles, they may have 
different functions and capacities to promote regeneration. Indeed, pericytes 
and adventitial cells have different abilities to promote angiogenesis after hind 
limb ischemia (Gonzalez et al., in preparation). Moreover,  perivascular cells 




adventitial cells and pericytes resulted in better bone regeneration (Wang et 
al. 2019).  
 
In addition to transcriptomic differences between adventitial cells and pericytes 
in culture, the use of freshly sorted cells may also be better for cell therapy. 
Indeed, cells are similar in vitro and differ from their native identity. Others have 
used ALDH high cells with good results. However, freshly isolated cells were 
used for this experiment (Capoccia et al., 2009). Therefore, more studies of 
how culture expansion may affect clinical efficacy are required. It is also worth 
mentioning that the ALDH high compartment contains other subsets of 
perivascular cells. 
 
Finally, a novel marker for perivascular cells was identified. ALDH1A1, a stem 
cell marker, was found expressed in a subset of perivascular cells, especially 
in the adventitial layer of large vessels. This sub-population of adventitial cells 
may have specific functions in homeostasis and during injury, including acting 
as progenitors for myofibroblasts and muscle cells. However, an animal model 
where cells expressing ALDH1A1 are tagged is needed to analyse their 
contribution in injury and aging. Furthermore, ALDH1A1 was also expressed 
in a subset of pericytes in glioblastoma multiforme. These pericytes may be 
the drivers of angiogenesis for tumour growth as it has been demonstrated for 
tumour derived endothelial cells. Lastly, ALDH1A1 was expressed upon injury 




conclusive it is indicative that ALDH1A1 expression may be needed for cells 
to proliferate and differentiate.  
 
In conclusion, our results show that ALDH high adventitial cells in large vessels 
have a different transcriptome compared to ALDH low adventitial cells and 
pericytes and that the ALDH1A1 isoform is the enzyme active in the ALDH high 
compartment. Furthermore, we also documented how culture conditions 
change these perivascular cells once they become mesenchymal stem cells 
in vitro. We obtained preliminary data of perivascular cells expressing 
ALDH1A1 in brain cancer that may be involved in tumour growth. Finally, using 
two injury models, we found that ALDH1A1 is expressed by perivascular cells 
and muscle cells after injury, suggesting that ALDH1A1 is involved in the 











6.2 Considerations for the future  
MSCs come from perivascular cells and are used in many different disease 
settings. However, the following questions need to be answered in order to 
properly assess consistency of their use in cell therapy: 
• Do pericytes and adventitial cells have different regenerative 
capacities after they become MSCs? 
 
• Is there competitive advantage of one of the types of MSC progenitors 
and how consistent between donors will it be? 
 
• Do MSCs derived from perivascular cells from different organs have 
differential tissue specific regenerative capacity? 
 
 
Lastly, in order to complement the results found in this thesis, the following 
needs to be performed: 
• Increase the donor pool for the in vitro analyses  
• Do RNA sequencing in the ALDH subsets to have a sample size of at 
least 3 and perform statistics on them 
• Perform injury in an animal model where ALDH1A1 cells are labelled 
to track them upon injury 
• Inject freshly sorted and cultured ALDH high cells to further analyse 
what conditions may be better for therapeutics, culture expanded or 
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